James D. Brooks

5.0/5

34 Patient Ratings

276 Patient Reviews

Professional Summary

Education & Certifications

Medical Education: Stanford University School of Medicine (1988) CA
Residency: Johns Hopkins University Surgery Program (1990) MD
Internship: Johns Hopkins University Surgery Program (1989) MD
- Fellowship: Johns Hopkins University School of Medicine (1997) MD
- Residency: Johns Hopkins University School of Medicine (1994) MD
- Board Recertification, Urology, American Board of Urology (2017)
- Board Certification: American Board of Urology, Urology (2000)
- A. B., University of Chicago, Biology (1982)

View More Education & Certifications

Honors & Awards

Best Doctors in America, Best Doctors Inc. (2004-2013)
Clinician Scientist Award, Doris Duke Foundation (1998-2002)
Dornier Research Scholar, American Foundation for Urologic Disease (1995-1997)
- Eugene P. Schonfeld Medical Research Award, Kidney Cancer Association (2000-2002)
- Keith and Jan Hurlbut Professor, Stanford University (2012)
- Leutje-Stubbs Faculty Scholar, Stanford University School of Medicine (2002-2003)
- Listing in Guide to America's Top Surgeons, Consumers' Research Council (2010)

View More Honors & Awards

Memberships

Executive Member, Society for Basic Urologic Research (2021 - Present)

Administrative Appointments

Acting Chair, Department of Urology (2012 - 2012)
Associate Chair, Prostate Cancer Working Group EDRN (2010 - 2015)
Associate Dean, Academic Affairs, Stanford University School of Medicine (2013 - 2019)
- Chief, Urologic Oncology, Department of Urology (2012 - Present)
- Co-Chair, Molecular and Cellular Characterization Centers NCI (2015 - 2017)
- Director, U54 Stanford O'Brien Urology Research Center (2021 - Present)
- Editor-in-Chief, The Open Prostate Cancer Journal (2008 - 2015)
- Editorial Board, The Prostate (2000 - Present)
- Editorial Board, Prostate Cancer (2010 - 2015)
- Editorial Board, Andrology (2011 - Present)
- Membership Committee, Society for Basic Urologic Research (2004 - 2008)
- Nominating Committee, Society of Basic Urologic Research (2015 - 2017)
- Vice Chair, Department of Urology (2014 - Present)

View More Administrative Appointments

Publications

UPJ obstruction: assessing minimally invasive therapies.
Moore, R. G., & Brooks, J. D. (1995). UPJ obstruction: assessing minimally invasive therapies. Contemporary Urology, 7(12), 47-?
Partial nephrectomy and caval thrombectomy for renal cell carcinoma in a solitary kidney with an accessory renal vein
Pruthi, R. S., Angell, S. K., Brooks, J. D., & Gill, H. (1999). Partial nephrectomy and caval thrombectomy for renal cell carcinoma in a solitary kidney with an accessory renal vein. BJU INTERNATIONAL, 83(1), 142–43.
GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas
Tchou, J. C., Lin, X. H., Freije, D., Isaacs, W. B., Brooks, J. D., Rashid, A., … Nelson, W. G. (2000). GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. INTERNATIONAL JOURNAL OF ONCOLOGY, 16(4), 663–676.
- Absence of HinfI restriction abnormalities in renal oncocytoma mitochondrial DNA
  Brooks, J. D., Marshall, F. F., Isaacs, W. B., & Johns, D. R. (1999). Absence of HinfI restriction abnormalities in renal oncocytoma mitochondrial DNA. MOLECULAR UROLOGY, 3(1), 1–3.
- New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents
  Williams, E. D., & Brooks, J. D. (2001). New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents. UROLOGY, 57(4A), 100–102.
- Role of cytologic criteria in the histologic diagnosis of gleason grade 1 prostatic adenocarcinoma
  McNeal, J. E., Cohen, R. J., & Brooks, J. D. (2001). Role of cytologic criteria in the histologic diagnosis of gleason grade 1 prostatic adenocarcinoma. HUMAN PATHOLOGY, 32(4), 441–46.
- Prevention of prostate cancer
  DePrimo, S. E., Shinghal, R., Vidanes, G., & Brooks, J. D. (2001). Prevention of prostate cancer. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 15(3), 445-?
- Potent induction of phase 2 enzymes in human prostate cells by sulforaphane
  Brooks, J. D., Paton, V. G., & Vidanes, G. (2001). Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 10(9), 949–54.
- GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells
  Lin, X. H., Tascilar, M., Lee, W. H., Vles, W. J., Lee, B. H., Veeraswamy, R., … Nelson, W. G. (2001). GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. AMERICAN JOURNAL OF PATHOLOGY, 159(5), 1815–1826.
- Plasma selenium level before diagnosis and the risk of prostate cancer development
  Brooks, J. D., Metter, E. J., Chan, D. W., Sokoll, L. J., Landis, P., Nelson, W. G., … Carter, H. B. (2001). Plasma selenium level before diagnosis and the risk of prostate cancer development. JOURNAL OF UROLOGY, 166(6), 2034–38.
- Preneoplastic prostate lesions - An opportunity for prostate cancer prevention
  Nelson, W. G., De Marzo, A. M., DeWeese, T. L., Lin, X. H., Brooks, J. D., Putzi, M. J., … Kensler, T. W. (2001). Preneoplastic prostate lesions - An opportunity for prostate cancer prevention. Presented at the 4th Strang International Cancer Prevention Conference, NEW YORK,NY: NEW YORK ACAD SCIENCES.
- Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells
  Schwarze, S. R., DePrimo, S. E., Grabert, L. M., Fu, V. X., Brooks, J. D., & Jarrard, D. F. (2002). Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. JOURNAL OF BIOLOGICAL CHEMISTRY, 277(17), 14877–14883.
- Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells
  Vidanes, G. M., Paton, V., Wallen, E., Peehl, D. M., Navone, N., & Brooks, J. D. (2002). Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. PROSTATE, 51(4), 225–30.
- Anatomy of the rectourethralis muscle
  Brooks, J. D., Eggener, S. E., & Chao, W. M. (2002). Anatomy of the rectourethralis muscle. EUROPEAN UROLOGY, 41(1), 94–100.
- Microarray analysis in prostate cancer research.
  Brooks, J. D. (2002). Microarray analysis in prostate cancer research. Current Opinion in Urology, 12(5), 395–99.
- Transcriptional programs activated by exposure of human prostate cancer cells to androgen
  DePrimo, S. E., Diehn, M., Nelson, J. B., Reiter, R. E., Matese, J., Fero, M., … Brooks, J. D. (2002). Transcriptional programs activated by exposure of human prostate cancer cells to androgen. GENOME BIOLOGY, 3(7).
- Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis
  Shibata, A., Garcia, M. I., Cheng, I., Stamey, T. A., McNeal, J. E., Brooks, J. D., … Peehl, D. M. (2002). Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. PROSTATE, 52(4), 269–78.
- Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro
  Brooks, J. D., Goldberg, M. F., Nelson, L. A., Wu, D., & Nelson, W. G. (2002). Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 11(9), 868–75.
- Potent induction of carcinogen defence enzymes with sulforaphane, a putative prostate cancer chemopreventive agent.
  Brooks, J. D., & Paton, V. (1999). Potent induction of carcinogen defence enzymes with sulforaphane, a putative prostate cancer chemopreventive agent. Prostate Cancer and Prostatic Diseases, 2(S3), S8.
- Expression of FKBP12 in benign and malignant vascular endothelium - An immunohistochemical study on conventional sections and tissue microarrays
  Higgins, J. P. T., Montgomery, K., Wang, L. L., Domanay, E., Warnke, R. A., Brooks, J. D., & van de Rijn, M. (2003). Expression of FKBP12 in benign and malignant vascular endothelium - An immunohistochemical study on conventional sections and tissue microarrays. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 27(1), 58–64.
- Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray
  Higgins, J. P. T., Shinghal, R., Gill, H., Reese, J. H., Terris, M., Cohen, R. J., … Brooks, J. D. (2003). Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. AMERICAN JOURNAL OF PATHOLOGY, 162(3), 925–32.
- Differential gene-expression patterns in genital fibroblasts of normal males and 46,XY females with androgen insensitivity syndrome: evidence for early programming involving the androgen receptor
  Holterhus, P. M., Hiort, O., Demeter, J., Brown, P. O., & Brooks, J. D. (2003). Differential gene-expression patterns in genital fibroblasts of normal males and 46,XY females with androgen insensitivity syndrome: evidence for early programming involving the androgen receptor. GENOME BIOLOGY, 4(6).
- Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors
  Sperger, J. M., Chen, X., Draper, J. S., Antosiewicz, J. E., Chon, C. H., Jones, S. B., … Thomson, J. A. (2003). Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100(23), 13350–55.
- Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells
  Zhao, H. J., Whitfield, M. L., Xu, T., Botstein, D., & Brooks, J. D. (2004). Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. MOLECULAR BIOLOGY OF THE CELL, 15(2), 506–19.
- Gene expression in the normal adult human kidney assessed by complementary DNA microarray
  Higgins, J. P. T., Wang, L. L., Kambham, N., Montgomery, K., Mason, V., Vogelmann, S. U., … van de Rijn, M. (2004). Gene expression in the normal adult human kidney assessed by complementary DNA microarray. MOLECULAR BIOLOGY OF THE CELL, 15(2), 649–56.
- Gene expression profiling identifies clinically relevant subtypes of prostate cancer
  Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., … Pollack, J. R. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 101(3), 811–16.
- Biochemical remission after resection of prostate cancer lung metastasis
  Chao, D. H., Higgins, J. P. T., & Brooks, J. D. (2004). Biochemical remission after resection of prostate cancer lung metastasis. UROLOGY, 63(3).
- Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays
  Krishnan, A. V., Shinghal, R., Raghavachari, N., Brooks, J. D., Peehl, D. M., & Feldman, D. (2004). Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. PROSTATE, 59(3), 243–51.
- Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population
  Presti, J. C., Lee, U., Brooks, J. D., & Terris, M. K. (2004). Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. JOURNAL OF UROLOGY, 171(6), 2199–2202.
- Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes?
  King, C. R., Presti, J. C., Gill, H., Brooks, J., & Hancock, S. L. (2004). Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes? INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 59(2), 341–47.
- Time trends in pathologic features of radical prostatectomy - impact of family history
  Marotte, J. B., Ferrari, M. K., McNeal, J. E., Brooks, J. D., & Presti, J. C. (2004). Time trends in pathologic features of radical prostatectomy - impact of family history. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 22(3), 169–73.
- Molecular targets of Doxazosin in human prostatic stromal cells
  Zhao, H. J., Lai, F., Nonn, L., Brooks, J. D., & Peehl, D. M. (2005). Molecular targets of Doxazosin in human prostatic stromal cells. PROSTATE, 62(4), 400–410.
- Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines
  Zhao, H. J., Kim, Y., Wang, P., Lapointe, J., Tibshirani, R., Pollack, J. R., & Brooks, J. D. (2005). Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. PROSTATE, 63(2), 187–97.
- Vascular invasion predicts recurrence after radical prostatectomy: Stratification of risk based on pathologic variables
  Ferrari, M. K., McNeal, J. E., Malhotra, S. M., & Brooks, J. D. (2004). Vascular invasion predicts recurrence after radical prostatectomy: Stratification of risk based on pathologic variables. UROLOGY, 64(4), 749–53.
- Molecular activity of 1,25-dihydroxyvitamin D-3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis
  Peehl, D. M., Shinghal, R., Nonn, L., Seto, E., Krishnan, A. V., Brooks, J. D., & Feldman, D. (2004). Molecular activity of 1,25-dihydroxyvitamin D-3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 92(3), 131–41.
- A transcriptional profile of aging in the human kidney
  Rodwell, G. E. J., Sonu, R., Zahn, J. M., Lund, J., Wilhelmy, J., Wang, L. L., … Kim, S. K. (2004). A transcriptional profile of aging in the human kidney. PLOS BIOLOGY, 2(12), 2191–2201.
- Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy
  Lee, K. L., Marotte, J. B., Ferrari, M. K., McNeal, J. E., Brooks, J. D., & Presti, J. C. (2005). Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy. UROLOGY, 65(2), 311–15.
- Resveratrol-induced gene expression profiles in human prostate cancer cells
  Jones, S. B., DePrimo, S. E., Whitfield, M. L., & Brooks, J. D. (2005). Resveratrol-induced gene expression profiles in human prostate cancer cells. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 14(3), 596–604.
- Reg IV: A promising marker of hormone refractory metastatic prostate cancer
  Gu, Z. N., Rubin, M. A., Yang, Y., DePrimo, S. E., Zhao, H. J., Horvath, S., … Reiter, R. E. (2005). Reg IV: A promising marker of hormone refractory metastatic prostate cancer. CLINICAL CANCER RESEARCH, 11(6), 2237–2243.
- Juvenile posttraumatic high-flow priapism: current management dilemmas
  Marotte, J. B., Brooks, J. D., Sze, D., & Kennedy, W. A. (2005). Juvenile posttraumatic high-flow priapism: current management dilemmas. JOURNAL OF PEDIATRIC SURGERY, 40(4).
- Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy
  Patel, D. A., Presti, J. C., McNeal, J. E., Gill, H., Brooks, J. D., & King, C. R. (2005). Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. JOURNAL OF CLINICAL ONCOLOGY, 23(25), 6157–62.
- The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer
  Kim, H., Lapointe, J., Kaygusuz, G., Ong, D. E., Li, C. D., van de Rijn, M., … Pollack, J. R. (2005). The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. CANCER RESEARCH, 65(18), 8118–24.
- Gene expression profiling predicts survival in conventional renal cell carcinoma
  Zhao, H. J., Ljungberg, B., Grankvist, K., Rasmuson, T., Tibshirani, R., & Brooks, J. D. (2006). Gene expression profiling predicts survival in conventional renal cell carcinoma. PLOS MEDICINE, 3(1), 115–24.
- Modest induction of phase 2 enzyme activity in the F-344 rat prostate
  Jones, S. B., & Brooks, J. D. (2006). Modest induction of phase 2 enzyme activity in the F-344 rat prostate. BMC CANCER, 6.
- Endothelin-1 promotes cell survival in renal cell carcinoma through the ETA receptor
  Pflug, B. R., Zheng, H., Udan, M. S., D'Antonio, J. M., Marshall, F. F., Brooks, J. D., & Nelson, J. B. (2007). Endothelin-1 promotes cell survival in renal cell carcinoma through the ETA receptor. CANCER LETTERS, 246(1-2), 139–148.
- Refractory hematuria from amyloidosis successfully treated by splenectomy
  Ma, J. F., Coutre, S. E., Curet, M. J., & Brooks, J. D. (2006). Refractory hematuria from amyloidosis successfully treated by splenectomy. UROLOGY, 67(5).
- Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade
  King, C. R., McNeal, J. E., Gill, H., Brooks, J. D., Srinivas, S., & Presti, J. C. (2006). Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. UROLOGY, 67(6), 1229–34.
- Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription
  Bebermeier, J.-H., Brooks, J. D., DePrimo, S. E., Werner, R., Deppe, U., Demeter, J., … Holterhus, P.-M. (2006). Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription. JOURNAL OF MOLECULAR MEDICINE-JMM, 84(11), 919–931.
- Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues
  Zhao, H., Ramos, C. F., Brooks, J. D., & Peehl, D. M. (2007). Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. JOURNAL OF CELLULAR PHYSIOLOGY, 210(1), 111–21.
- Application of genomic technologies to human prostate cancer
  Li, S., Bhamre, S., Lapointe, J., Pollack, J. R., & Brooks, J. D. (2006). Application of genomic technologies to human prostate cancer. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 10(3), 261–75.
- Selenomethionine induced transcriptional programs in human prostate cancer cells
  Zhao, H., & Brooks, J. D. (2007). Selenomethionine induced transcriptional programs in human prostate cancer cells. JOURNAL OF UROLOGY, 177(2), 743–50.
- A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis
  Lapointe, J., Kim, Y. H., Miller, M. A., Li, C., Kaygusuz, G., van de Rijn, M., … Pollack, J. R. (2007). A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. MODERN PATHOLOGY, 20(4), 467–73.
- A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells
  Li, T.-H., Zhao, H., Peng, Y., Beliakoff, J., Brooks, J. D., & Sun, Z. (2007). A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. NUCLEIC ACIDS RESEARCH, 35(8), 2767–76.
- Placental S100 (S100P) and GATA3: Markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray
  Higgins, J. P. T., Kaygusuz, G., Wang, L., Montgomery, K., Mason, V., Zhu, S. X., … Brooks, J. D. (2007). Placental S100 (S100P) and GATA3: Markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 31(5), 673–80.
- Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis
  Lapointe, J., Li, C., Giacomini, C. P., Salari, K., Huang, S., Wang, P., … Pollack, J. R. (2007). Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. CANCER RESEARCH, 67(18), 8504–10.
- Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy
  King, C. R., Presti, J. C., Brooks, J. D., Gill, H., & Spiotto, M. T. (2008). Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70(5), 1472–77.
- Intrinsic androgen-dependent gene expression patterns revealed by comparison of genital fibroblasts from normal males and individuals with complete and partial androgen insensitivity syndrome
  Holterhus, P.-M., Deppe, U., Werner, R., Richter-Unruh, A., Bebermeier, J.-H., Wuensch, L., … Brooks, J. D. (2007). Intrinsic androgen-dependent gene expression patterns revealed by comparison of genital fibroblasts from normal males and individuals with complete and partial androgen insensitivity syndrome. BMC GENOMICS, 8.
- hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature
  Lapointe, J., Malhotra, S., Higgins, J. P., Bair, E., Thompson, M., Salari, K., … Pollack, J. R. (2008). hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 32(2), 205–9.
- Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle
  Thompson, M., Lapointe, J., Choi, Y.-L., Ong, D. E., Higgins, J. P., Brooks, J. D., & Pollack, J. R. (2008). Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle. PROSTATE, 68(11), 1248–56.
- Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer.
  Zhang, H., Dong, Y., Zhao, H., Brooks, J. D., Hawthorn, L., Nowak, N., … Ip, C. (2005). Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. Cancer Genomics & Proteomics, 2(2), 97–114.
- STEREOTACTIC BODY RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER: INTERIM RESULTS OF A PROSPECTIVE PHASE II CLINICAL TRIAL
  King, C. R., Brooks, J. D., Gill, H., Pawlicki, T., Cotrutz, C., & Presti, J. C. (2009). STEREOTACTIC BODY RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER: INTERIM RESULTS OF A PROSPECTIVE PHASE II CLINICAL TRIAL. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 73(4), 1043–48.
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
  Chin, L., Meyerson, M., Aldape, K., Bigner, D., Mikkelsen, T., VandenBerg, S., … Thomson, E. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. NATURE, 455(7216), 1061–68.
- Prognostic significance of prostate cancer originating from the transition zone
  King, C. R., Ferrari, M., & Brooks, J. D. (2009). Prognostic significance of prostate cancer originating from the transition zone. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 27(6), 592–97.
- Temporal Changes in Gene Expression Induced by Sulforaphane in Human Prostate Cancer Cells
  Bhamre, S., Sahoo, D., Tibshirani, R., Dill, D. L., & Brooks, J. D. (2009). Temporal Changes in Gene Expression Induced by Sulforaphane in Human Prostate Cancer Cells. PROSTATE, 69(2), 181–90.
- Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients
  Swami, S., Krishnan, A. V., Moreno, J., Bhattacharya, R. S., Gardner, C., Brooks, J. D., … Feldman, D. (2009). Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. INTERNATIONAL JOURNAL OF CANCER, 124(9), 2050–59.
- Prostatic Soy Isoflavone Concentrations Exceed Serum Levels After Dietary Supplementation
  Gardner, C. D., Oelrich, B., Liu, J. P., Feldman, D., Franke, A. A., & Brooks, J. D. (2009). Prostatic Soy Isoflavone Concentrations Exceed Serum Levels After Dietary Supplementation. PROSTATE, 69(7), 719–26.
- Recommendations for the reporting of surgically resected specimens of renal cell carcinoma The Association of Directors of Anatomic and Surgical Pathology
  Higgins, J. P., McKenney, J. K., Brooksd, J. D., Argani, P., & Epstein, J. I. (2009). Recommendations for the reporting of surgically resected specimens of renal cell carcinoma The Association of Directors of Anatomic and Surgical Pathology. HUMAN PATHOLOGY, 40(4), 456–63.
- Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen insensitivity syndrome
  Appari, M., Werner, R., Wuensch, L., Cario, G., Demeter, J., Hiort, O., … Holterhus, P.-M. (2009). Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen insensitivity syndrome. JOURNAL OF MOLECULAR MEDICINE-JMM, 87(6), 623–632.
- Recommendations for the Reporting of Surgically Resected Specimens of Renal Cell Carcinoma
  Higgins, J. P., McKenney, J. K., Brooks, J. D., Argani, P., & Epstein, J. I. (2009). Recommendations for the Reporting of Surgically Resected Specimens of Renal Cell Carcinoma. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 131(5), 623-?
- Alteration of Gene Expression Signatures of Cortical Differentiation and Wound Response in Lethal Clear Cell Renal Cell Carcinomas
  Zhao, H., Ma, Z., Tibshirani, R., Higgins, J. P. T., Ljungberg, B., & Brooks, J. D. (2009). Alteration of Gene Expression Signatures of Cortical Differentiation and Wound Response in Lethal Clear Cell Renal Cell Carcinomas. PLOS ONE, 4(6).
- Disorders of sex development expose transcriptional autonomy of genetic sex and androgen-programmed hormonal sex in human blood leukocytes
  Holterhus, P.-M., Bebermeier, J.-H., Werner, R., Demeter, J., Richter-Unruh, A., Cario, G., … Hiort, O. (2009). Disorders of sex development expose transcriptional autonomy of genetic sex and androgen-programmed hormonal sex in human blood leukocytes. BMC GENOMICS, 10.
- Canary Prostate Active Surveillance Study: Design of a Multi-institutional Active Surveillance Cohort and Biorepository
  Newcomb, L. F., Brooks, J. D., Carroll, P. R., Feng, Z., Gleave, M. E., Nelson, P. S., … Lin, D. W. (2010). Canary Prostate Active Surveillance Study: Design of a Multi-institutional Active Surveillance Cohort and Biorepository. UROLOGY, 75(2), 407–13.
- Comparison of prostate cancer tumor volume and percent cancer in prediction of biochemical recurrence and cancer specific survival
  Chung, B. I., Tarin, T. V., Ferrari, M., & Brooks, J. D. (2011). Comparison of prostate cancer tumor volume and percent cancer in prediction of biochemical recurrence and cancer specific survival. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 29(3), 314–18.
- CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.
  Williams, A. A., Higgins, J. P. T., Zhao, H., Ljunberg, B., & Brooks, J. D. (2009). CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clinical Pathology, 9, 9-?
- The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis
  Quick, C. M., Gokden, N., Sangoi, A. R., Brooks, J. D., & McKenney, J. K. (2010). The distribution of PAX-2 immunoreactivity in the prostate gland, seminal vesicle, and ejaculatory duct: comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis. HUMAN PATHOLOGY, 41(8), 1145–49.
- Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns.
  Brannon, A. R., Reddy, A., Seiler, M., Arreola, A., Moore, D. T., Pruthi, R. S., … Rathmell, W. K. (2010). Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes & Cancer, 1(2), 152–163.
- Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: a study of 305 cases
  Sangoi, A. R., Karamchandani, J., Lane, B., Higgins, J. P., Rouse, R. V., Brooks, J. D., & McKenney, J. K. (2011). Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors: a study of 305 cases. MODERN PATHOLOGY, 24(3), 425–29.
- LONG-TERM OUTCOMES FROM A PROSPECTIVE TRIAL OF STEREOTACTIC BODY RADIOTHERAPY FOR LOW-RISK PROSTATE CANCER
  King, C. R., Brooks, J. D., Gill, H., & Presti, J. C. (2012). LONG-TERM OUTCOMES FROM A PROSPECTIVE TRIAL OF STEREOTACTIC BODY RADIOTHERAPY FOR LOW-RISK PROSTATE CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(2), 877–882.
- Small Prostate Size and High Grade Disease-Biology or Artifact?
  Liu, J.-J., Brooks, J. D., Ferrari, M., Nolley, R., & Presti, J. C. (2011). Small Prostate Size and High Grade Disease-Biology or Artifact? JOURNAL OF UROLOGY, 185(6), 2108–11.
- DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer
  Kobayashi, Y., Absher, D. M., Gulzar, Z. G., Young, S. R., McKenney, J. K., Peehl, D. M., … Sherlock, G. (2011). DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. GENOME RESEARCH, 21(7), 1017–27.
- A Tri-Marker Proliferation Index Predicts Biochemical Recurrence after Surgery for Prostate Cancer
  Malhotra, S., Lapointe, J., Salari, K., Higgins, J. P., Ferrari, M., Montgomery, K., … Pollack, J. R. (2011). A Tri-Marker Proliferation Index Predicts Biochemical Recurrence after Surgery for Prostate Cancer. PLOS ONE, 6(5).
- The Potential Impact of Reproducibility of Gleason Grading in Men With Early Stage Prostate Cancer Managed by Active Surveillance: A Multi-Institutional Study
  McKenney, J. K., Simko, J., Bonham, M., True, L. D., Troyer, D., Hawley, S., … Brooks, J. D. (2011). The Potential Impact of Reproducibility of Gleason Grading in Men With Early Stage Prostate Cancer Managed by Active Surveillance: A Multi-Institutional Study. JOURNAL OF UROLOGY, 186(2), 465–69.
- Integrated genomic analyses of ovarian carcinoma
  Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D. W., Dao, F., … Thomson, E. (2011). Integrated genomic analyses of ovarian carcinoma. NATURE, 474(7353), 609–15.
- Smoking and adverse outcomes at radical prostatectomy
  Ngo, T. C., Lee, J. J., Brooks, J. D., Nolley, R., Ferrari, M., & Presti, J. C. (2013). Smoking and adverse outcomes at radical prostatectomy. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 31(6), 749–54.
- Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness
  Huang, S., Gulzar, Z. G., Salari, K., Lapointe, J., Brooks, J. D., & Pollack, J. R. (2012). Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. ONCOGENE, 31(37), 4164–70.
- Translational genomics: The challenge of developing cancer biomarkers
  Brooks, J. D. (2012). Translational genomics: The challenge of developing cancer biomarkers. GENOME RESEARCH, 22(2), 183–87.
- Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1
  Gulzar, Z. G., McKenney, J. K., & Brooks, J. D. (2013). Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1. ONCOGENE, 32(1), 70–77.
- Deficiency in Mammalian Histone H2B Ubiquitin Ligase Bre1 (Rnf20/Rnf40) Leads to Replication Stress and Chromosomal Instability
  Chernikova, S. B., Razorenova, O. V., Higgins, J. P., Sishc, B. J., Nicolau, M., Dorth, J. A., … Brown, J. M. (2012). Deficiency in Mammalian Histone H2B Ubiquitin Ligase Bre1 (Rnf20/Rnf40) Leads to Replication Stress and Chromosomal Instability. CANCER RESEARCH, 72(8), 2111–19.
- Methods for registration of magnetic resonance images of ex vivo prostate specimens with histology
  Kimm, S. Y., Tarin, T. V., Lee, J. H., Hu, B., Jensen, K., Nishimura, D., & Brooks, J. D. (2012). Methods for registration of magnetic resonance images of ex vivo prostate specimens with histology. JOURNAL OF MAGNETIC RESONANCE IMAGING, 36(1), 206–12.
- Evaluation of Putative Renal Cell Carcinoma Markers PAX-2, PAX-8, and hKIM-1 in Germ Cell Tumors: A Tissue Microarray Study of 100 Cases
  Sangoi, A. R., McKenney, J. K., Brooks, J. D., Bonventre, J. V., & Higgins, J. P. (2012). Evaluation of Putative Renal Cell Carcinoma Markers PAX-2, PAX-8, and hKIM-1 in Germ Cell Tumors: A Tissue Microarray Study of 100 Cases. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(5), 451–53.
- Performance Characteristics of Prostate-specific Antigen in Patients Undergoing Radical Prostatectomy
  Liu, J.-J., Ferrari, M., Nolley, R., Brooks, J. D., & Presti, J. C. (2012). Performance Characteristics of Prostate-specific Antigen in Patients Undergoing Radical Prostatectomy. UROLOGY, 79(6), 1336–39.
- Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence
  Truong, M., Yang, B., Wagner, J., Kobayashi, Y., Rajamanickam, V., Brooks, J., & Jarrard, D. F. (2012). Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence. BRITISH JOURNAL OF CANCER, 107(1), 100–107.
- Gene Expression Changes Induced by Unilateral Ureteral Obstruction in Mice
  Wu, B., & Brooks, J. D. (2012). Gene Expression Changes Induced by Unilateral Ureteral Obstruction in Mice. JOURNAL OF UROLOGY, 188(3), 1033–41.
- mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer
  Cann, G. M., Gulzar, Z. G., Cooper, S., Li, R., Luo, S., Tat, M., … Talasaz, A. A. H. (2012). mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer. PLOS ONE, 7(11).
- Evaluation of SF-1 Expression in Testicular Germ Cell Tumors: A Tissue Microarray Study of 127 Cases.
  Sangoi, A. R., McKenney, J. K., Brooks, J. D., & Higgins, J. P. (2013). Evaluation of SF-1 Expression in Testicular Germ Cell Tumors: A Tissue Microarray Study of 127 Cases. Applied Immunohistochemistry & Molecular Morphology , 21(4), 318–21.
- Comprehensive gene expression changes associated with mouse postnatal kidney development.
  Wu, B., Sahoo, D., & Brooks, J. D. (2013). Comprehensive gene expression changes associated with mouse postnatal kidney development. Journal of Urology, 189(6), 2385–90.
- A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers: The Canary Prostate Cancer Tissue Microarray
  Hawley, S., Fazli, L., McKenney, J. K., Simko, J., Troyer, D., Nicolas, M., … Brooks, J. D. (2013). A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers: The Canary Prostate Cancer Tissue Microarray. ADVANCES IN ANATOMIC PATHOLOGY, 20(1), 39–44.
- Identification and Characterization of 2 Testicular Germ Cell Markers, Glut3 and CyclinA2
  Howitt, B. E., Brooks, J. D., Jones, S., & Higgins, J. P. T. (2013). Identification and Characterization of 2 Testicular Germ Cell Markers, Glut3 and CyclinA2. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 21(5), 401–7.
- Epigenetic changes in histologically normal prostate tissues.
  Brooks, J. D. (2013). Epigenetic changes in histologically normal prostate tissues. Journal of Urology, 189(6), 2020–2021.
- Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study
  Lin, D. W., Newcomb, L. F., Brown, E. C., Brooks, J. D., Carroll, P. R., Feng, Z., … Nelson, P. S. (2013). Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study. CLINICAL CANCER RESEARCH, 19(9), 2442–50.
- DOPAMINE UPTAKE BLOCKERS PROTECT AGAINST THE DOPAMINE DEPLETING EFFECT OF 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) IN THE MOUSE STRIATUM
  Ricaurte, G. A., Langston, J. W., DeLanney, L. E., Irwin, I., & Brooks, J. D. (1985). DOPAMINE UPTAKE BLOCKERS PROTECT AGAINST THE DOPAMINE DEPLETING EFFECT OF 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) IN THE MOUSE STRIATUM. NEUROSCIENCE LETTERS, 59(3), 259–264.
- COMPARISON OF OPEN AND ENDOUROLOGICAL APPROACHES TO THE OBSTRUCTED URETEROPELVIC JUNCTION
  Brooks, J. D., Kavoussi, L. R., Preminger, G. M., Schuessler, W. W., & Moore, R. G. (1995). COMPARISON OF OPEN AND ENDOUROLOGICAL APPROACHES TO THE OBSTRUCTED URETEROPELVIC JUNCTION. UROLOGY, 46(6), 791–795.
- FREQUENT LOSS OF CHROMOSOME ARMS 8P AND 13Q IN COLLECTING DUCT CARCINOMA (CDC) OF THE KIDNEY
  Schoenberg, M., Cairns, P., Brooks, J. D., Marshall, F. F., Epstein, J. I., Isaacs, W. B., & Sidransky, D. (1995). FREQUENT LOSS OF CHROMOSOME ARMS 8P AND 13Q IN COLLECTING DUCT CARCINOMA (CDC) OF THE KIDNEY. GENES CHROMOSOMES & CANCER, 12(1), 76–80.
- GENETIC ALTERATIONS IN PROSTATE-CANCER
  Isaacs, W. B., Bova, G. S., Morton, R. A., Bussemakers, M. J. G., Brooks, J. D., & Ewing, C. M. (1994). GENETIC ALTERATIONS IN PROSTATE-CANCER. Presented at the 59th Cold Spring Harbor Symposium on Quantitative Biology - The Molecular Genetics of Cancer, COLD SPRING HARBOR,NY: COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT.
- MOLECULAR-BIOLOGY OF PROSTATE-CANCER PROGRESSION
  Isaacs, W. B., Bova, G. S., Morton, R. A., Bussemakers, M. J. G., Brooks, J. D., & Ewing, C. M. (1995). MOLECULAR-BIOLOGY OF PROSTATE-CANCER PROGRESSION. CANCER SURVEYS, 23, 19–32.
- ALLELIC LOSS OF THE RETINOBLASTOMA GENE IN PRIMARY HUMAN PROSTATIC ADENOCARCINOMAS
  Brooks, J. D., Bova, G. S., & Isaacs, W. B. (1995). ALLELIC LOSS OF THE RETINOBLASTOMA GENE IN PRIMARY HUMAN PROSTATIC ADENOCARCINOMAS. PROSTATE, 26(1), 35–39.
- LAPAROSCOPIC MANAGEMENT OF TESTICULAR PAIN AFTER EMBOLOTHERAPY OF VARICOCELE
  Brooks, J. D., Moore, R. G., & Kavoussi, L. R. (1994). LAPAROSCOPIC MANAGEMENT OF TESTICULAR PAIN AFTER EMBOLOTHERAPY OF VARICOCELE. JOURNAL OF ENDOUROLOGY, 8(5), 361–363.
- MOLECULAR-BIOLOGY OF PROSTATE-CANCER
  Isaacs, W. B., Bova, G. S., Morton, R. A., Bussemakers, M. J. G., Brooks, J. D., & Ewing, C. M. (1994). MOLECULAR-BIOLOGY OF PROSTATE-CANCER. SEMINARS IN ONCOLOGY, 21(5), 514–521.
- CYTIDINE METHYLATION OF REGULATORY SEQUENCES NEAR THE PI-CLASS GLUTATHIONE-S-TRANSFERASE GENE ACCOMPANIES HUMAN PROSTATIC CARCINOGENESIS
  Lee, W. H., Morton, R. A., Epstein, J. I., Brooks, J. D., Campbell, P. A., Bova, G. S., … Nelson, W. G. (1994). CYTIDINE METHYLATION OF REGULATORY SEQUENCES NEAR THE PI-CLASS GLUTATHIONE-S-TRANSFERASE GENE ACCOMPANIES HUMAN PROSTATIC CARCINOGENESIS. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 91(24), 11733–11737.
- TUBULARIZED NEOURETHRA FOLLOWING RADICAL RETROPUBIC PROSTATECTOMY
  Steiner, M. S., Burnett, A. L., Brooks, J. D., Brendler, C. B., STUTZMAN, R. E., & Carter, H. B. (1993). TUBULARIZED NEOURETHRA FOLLOWING RADICAL RETROPUBIC PROSTATECTOMY. JOURNAL OF UROLOGY, 150(2), 407–409.
- TUMOR-SUPPRESSOR GENE ALLELIC LOSS IN HUMAN RENAL CANCERS
  Brooks, J. D., Bova, G. S., Marshall, F. F., & Isaacs, W. B. (1993). TUMOR-SUPPRESSOR GENE ALLELIC LOSS IN HUMAN RENAL CANCERS. JOURNAL OF UROLOGY, 150(4), 1278–1283.
- An uncertain role for p53 gene alterations in human prostate cancers
  Brooks, J. D., Bova, G. S., Ewing, C. M., PIANTADOSI, S., Carter, B. S., Robinson, J. C., … Isaacs, W. B. (1996). An uncertain role for p53 gene alterations in human prostate cancers. CANCER RESEARCH, 56(16), 3814–3822.
- Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer
  Nelson, J. B., Lee, W. H., Nguyen, S. H., Jarrard, D. F., Brooks, J. D., Magnuson, S. R., … Bova, G. S. (1997). Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. CANCER RESEARCH, 57(1), 35–37.
- The Swedish prostate cancer paradox
  Walsh, P. C., & Brooks, J. D. (1997). The Swedish prostate cancer paradox. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 277(6), 497–498.
- Differentiation of colonic metaplasia from adenocarcinoma of urinary bladder
  JACOBS, L. B., Brooks, J. D., & Epstein, J. I. (1997). Differentiation of colonic metaplasia from adenocarcinoma of urinary bladder. HUMAN PATHOLOGY, 28(10), 1152–1157.
- Male pelvic anatomy reconstructed from the visible human data set
  Brooks, J. D., Chao, W. M., & Kerr, J. (1998). Male pelvic anatomy reconstructed from the visible human data set. JOURNAL OF UROLOGY, 159(3), 868–872.
- CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia
  Brooks, J. D., WEINSTEIN, M., Lin, X. H., Sun, Y. H., Pin, S. S., Bova, G. S., … Nelson, W. G. (1998). CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 7(6), 531–536.
- Regional DNA Hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors
  Regional DNA Hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. (1993). Cancer Research, 53.
- Mutations of the VHL tumour suppressor gene in renal carcinoma
  Mutations of the VHL tumour suppressor gene in renal carcinoma. (1994). Nature Genetics, 7.
- Epidemiologic and molecular features of prostate carcinogenesis as clues for new prostate cancer prevention strategies
  Epidemiologic and molecular features of prostate carcinogenesis as clues for new prostate cancer prevention strategies. (1996). Canadian Journal of Urology, 3(Supplement).
- Molecular staging of prostate cancer
  Molecular staging of prostate cancer. (1996). Canadian Journal of Urology, 3(Supplement).
- Embryonal adenoma of the kidney: case report
  Embryonal adenoma of the kidney: case report. (1995). Journal of Urology, 154.
- Genetic alterations in prostate cancer - prognostic implications?
  Genetic alterations in prostate cancer - prognostic implications? (1993). Akteulle Onkologie, 78.
- The impact of tumor volume on outcomes after radical prostatectomy: Implications for prostate cancer screening.
  The impact of tumor volume on outcomes after radical prostatectomy: Implications for prostate cancer screening. (2008). The Open Prostate Cancer Journal, 1.
- Gene expression changes induced by genistein in the prostate cancer cell line LNCaP
  Gene expression changes induced by genistein in the prostate cancer cell line LNCaP. (2010). The Open Prostate Cancer Journal, 3.
- Adjuvant docetaxel and abbreviated androgen deprivation therapy in patients with high risk prostate cancer
  Adjuvant docetaxel and abbreviated androgen deprivation therapy in patients with high risk prostate cancer. (2010). The Open Prostate Cancer Journal, 3.
- MOLECULAR-GENETICS AND CHROMOSOMAL ALTERATIONS IN PROSTATE-CANCER
  Isaacs, W. B., Bova, G. S., Morton, R. A., Bussemakers, M. J. G., Brooks, J. D., & Ewing, C. M. (1995). MOLECULAR-GENETICS AND CHROMOSOMAL ALTERATIONS IN PROSTATE-CANCER. CANCER, 75(7), 2004–2012.
- Length of site-specific positive surgical margins as a risk factor for biochemical recurrence following radical prostatectomy
  Hsu, M., Chang, S. L., Ferrari, M., Nolley, R., Presti, J. C., & Brooks, J. D. (2011). Length of site-specific positive surgical margins as a risk factor for biochemical recurrence following radical prostatectomy. INTERNATIONAL JOURNAL OF UROLOGY, 18(4), 272–279.
- Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
  Conti, S. L., Thomas, I.-C., Hagedorn, J. C., Chung, B. I., Chertow, G. M., Wagner, T. H., … Leppert, J. T. (2014). Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. International Journal of Cancer. Journal International Du Cancer, 134(9), 2245–52.
- Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape
  Day, K., Waite, L. L., Thalacker-Mercer, A., West, A., Bamman, M. M., Brooks, J. D., … Absher, D. (2013). Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. GENOME BIOLOGY, 14(9).
- Managing localized prostate cancer in the era of prostate-specific antigen screening.
  Brooks, J. D. (2013). Managing localized prostate cancer in the era of prostate-specific antigen screening. Cancer.
- Prostate cancer risk profiles of asian-american men: disentangling the effects of immigration status and race/ethnicity.
  Lichtensztajn, D. Y., Gomez, S. L., Sieh, W., Chung, B. I., Cheng, I., & Brooks, J. D. (2014). Prostate cancer risk profiles of asian-american men: disentangling the effects of immigration status and race/ethnicity. Journal of Urology, 191(4), 952–56.
- Utilization of renal mass biopsy in patients with renal cell carcinoma.
  Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Srinivas, S., Chertow, G. M., … Saigal, C. S. (2014). Utilization of renal mass biopsy in patients with renal cell carcinoma. Urology, 83(4), 774–80.
- Reply.
  Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Brooks, J. D., Srinivas, S., … Saigal, C. S. (2014). Reply. Urology, 83(4), 779–80.
- Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California.
  Sieh, W., Lichtensztajn, D. Y., Nelson, D. O., Cockburn, M., West, D. W., Brooks, J. D., & Chang, E. T. (2013). Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California. The Open Prostate Cancer Journal, 6, 1–9.
- Increased Expression of GCNT1 is Associated With Altered O-glycosylation of PSA, PAP, and MUC1 in Human Prostate Cancers
  Chen, Z., Gulzar, Z. G., St Hill, C. A., Walcheck, B., & Brooks, J. D. (2014). Increased Expression of GCNT1 is Associated With Altered O-glycosylation of PSA, PAP, and MUC1 in Human Prostate Cancers. PROSTATE, 74(10), 1059–67.
- The impact of robotic surgery on the surgical management of prostate cancer in the USA
  Chang, S. L., Kibel, A. S., Brooks, J. D., & Chung, B. I. (2015). The impact of robotic surgery on the surgical management of prostate cancer in the USA. BJU INTERNATIONAL, 115(6), 929–36.
- The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-(13)C]-ketoisocaproate.
  Billingsley, K. L., Park, J. M., Josan, S., Hurd, R., Mayer, D., Spielman-Sun, E., … Spielman, D. (2014). The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-(13)C]-ketoisocaproate. Magnetic Resonance Imaging, 32(7), 791–95.
- Novel Fusion Transcripts Associate with Progressive Prostate Cancer
  Yu, Y. P., Ding, Y., Chen, Z. H., Liu, S., Michalopoulos, A., Chen, R., … Luo, J.-H. (2014). Novel Fusion Transcripts Associate with Progressive Prostate Cancer. AMERICAN JOURNAL OF PATHOLOGY, 184(10), 2840–49.
- Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance
  Busch, J., Magheli, A., Leva, N., Ferrari, M., Kramer, J., Klopf, C., … Gonzalgo, M. L. (2014). Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance. BJU INTERNATIONAL, 114(4), 517–21.
- Biologic Differences Between Peripheral and Transition Zone Prostate Cancer
  Lee, J. J., Thomas, I.-C., Nolley, R., Ferrari, M., Brooks, J. D., & Leppert, J. T. (2015). Biologic Differences Between Peripheral and Transition Zone Prostate Cancer. PROSTATE, 75(2), 183–90.
- NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells.
  Gordon, C. A., Gulzar, Z. G., & Brooks, J. D. (2015). NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells. Prostate, 75(5), 517–26.
- DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma.
  Lasseigne, B. N., Burwell, T. C., Patil, M. A., Absher, D. M., Brooks, J. D., & Myers, R. M. (2014). DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. BMC Medicine, 12(1), 235.
- Increased Risk of Cancer in Infertile Men: Analysis of US Claims Data
  Eisenberg, M. L., Li, S., Brooks, J. D., Cullen, M. R., & Baker, L. C. (2015). Increased Risk of Cancer in Infertile Men: Analysis of US Claims Data. JOURNAL OF UROLOGY, 193(5), 1596–1601.
- Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma Reply
  Leppert, J. T., Hanley, J., Wagner, T. H., Chung, B. I., Brooks, J. D., Srinivas, S., … Saigal, C. S. (2014). Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma Reply. UROLOGY, 83(4), 779–80.
- Re: Nationwide prevalence of lymph node metastases in Gleason score 3?+?3?=?6 prostate cancer: authors' reply.
  Sieh, W., Lichtensztajn, D. Y., Gomez, S. L., Liu, J.-J., Chung, B. I., Cheng, I., & Brooks, J. D. (2015). Re: Nationwide prevalence of lymph node metastases in Gleason score 3?+?3?=?6 prostate cancer: authors' reply. Pathology, 47(4), 394–95.
- Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator
  Ankerst, D. P., Xia, J., Thompson, I. M., Hoefler, J., Newcomb, L. F., Brooks, J. D., … Lin, D. W. (2015). Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. EUROPEAN UROLOGY, 68(6), 1083–88.
- A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer
  Troyer, D. A., Jamaspishvili, T., Wei, W., Feng, Z., Good, J., Hawley, S., … Squire, J. A. (2015). A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. PROSTATE, 75(11), 1206–15.
- Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients
  Brooks, J. D., Wei, W., Hawley, S., Auman, H., Newcomb, L., Boyer, H., … McKenney, J. K. (2015). Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLOS ONE, 10(7).
- The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma
  Jamshidi, N., Jonasch, E., Zapala, M., Korn, R. L., Aganovic, L., Zhao, H., … Kuo, M. D. (2015). The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma. RADIOLOGY, 277(1), 114–23.
- GSTP1 Loss Results in Accumulation of Oxidative DNA Base Damage and Promotes Prostate Cancer Cell Survival Following Exposure to Protracted Oxidative Stress
  Mian, O. Y., Khattab, M. H., Hedayati, M., Coulter, J., Abubaker-Sharif, B., Schwaninger, J. M., … DeWeese, T. L. (2016). GSTP1 Loss Results in Accumulation of Oxidative DNA Base Damage and Promotes Prostate Cancer Cell Survival Following Exposure to Protracted Oxidative Stress. PROSTATE, 76(2), 199–206.
- A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers.
  Jokerst, J. V., Chen, Z., Xu, L., Nolley, R., Chang, E., Mitchell, B., … Gambhir, S. S. (2015). A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers. PloS One, 10(9), e0139484.
- Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort
  Newcomb, L. F., Thompson, I. M., Boyer, H. D., Brooks, J. D., Carroll, P. R., Cooperberg, M. R., … Lin, D. W. (2016). Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. JOURNAL OF UROLOGY, 195(2), 313–20.
- Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?
  Barbosa, P. V., Thomas, I.-C., Srinivas, S., Buyyounouski, M. K., Chung, B. I., Chertow, G. M., … Leppert, J. T. (2016). Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable? EUROPEAN UROLOGY, 70(2), 227–30.
- The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial
  Jamshidi, N., Jonasch, E., Zapala, M., Korn, R. L., Brooks, J. D., Ljungberg, B., & Kuo, M. D. (2016). The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. EUROPEAN RADIOLOGY, 26(8), 2798–2807.
- Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of > 1000 prostatectomies
  Tretiakova, M. S., Wei, W., Boyer, H. D., NEWCOMB, L. F., Hawley, S., Auman, H., … Brooks, J. D. (2016). Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of > 1000 prostatectomies. PROSTATE CANCER AND PROSTATIC DISEASES, 19(3), 264–70.
- Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH
  Lotan, T. L., Wei, W., Ludkovski, O., Morais, C. L., Guedes, L. B., Jamaspishvili, T., … Squire, J. A. (2016). Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. MODERN PATHOLOGY, 29(8), 904–14.
- Reply to being a widower may be an indication for routine prostate-specific antigen screening above age 69 years, which the American Urological Association recommends as a cutoff point.
  Gomez, S. L., Martínez, M. E., Brooks, J. D., Cheng, I., Lichtensztajn, D., & Murphy, J. D. (2016). Reply to being a widower may be an indication for routine prostate-specific antigen screening above age 69 years, which the American Urological Association recommends as a cutoff point. Cancer.
- Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort.
  Brooks, J. D., Wei, W., Pollack, J. R., West, R. B., Shin, J. H., Sunwoo, J. B., … Fazli, L. (2016). Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate, 76(15), 1409–19.
- New Paradigms for Patient-Centered Outcomes Research in Electronic Medical Records: An Example of Detecting Urinary Incontinence Following Prostatectomy.
  Hernandez-Boussard, T., Tamang, S., Blayney, D., Brooks, J., & Shah, N. (2016). New Paradigms for Patient-Centered Outcomes Research in Electronic Medical Records: An Example of Detecting Urinary Incontinence Following Prostatectomy. EGEMS (Washington, DC), 4(3), 1231-?
- Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries.
  Mittakanti, H. R., Thomas, I.-C. C., Shelton, J. B., Makarov, D. V., Skolarus, T. A., Cooperberg, M. R., … Leppert, J. T. (2016). Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology.
- Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy
  Shinghal, R., Yemoto, C., McNeal, J. E., & Brooks, J. D. (2003). Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. UROLOGY, 61(2), 380–385.
- Contemporary Use of Partial Nephrectomy: Are Older Patients With Impaired Kidney Function Being Left Behind?
  Leppert, J. T., Mittakanti, H. R., Thomas, I.-C., Lamberts, R. W., Sonn, G. A., Chung, B. I., … Brooks, J. D. (2016). Contemporary Use of Partial Nephrectomy: Are Older Patients With Impaired Kidney Function Being Left Behind? Urology.
- A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment
  Liss, M. A., Schenk, J. M., Faino, A. V., NEWCOMB, L. F., Boyer, H., Brooks, J. D., … THOMPSON, I. M. (2016). A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment. PROSTATE CANCER AND PROSTATIC DISEASES, 19(4), 390–94.
- PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.
  Lotan, T. L., Wei, W., Morais, C. L., Hawley, S. T., Fazli, L., Hurtado-Coll, A., … Brooks, J. D. (2016). PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. European Urology Focus, 2(2), 180–88.
- Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort
  McKenney, J. K., Wei, W., Hawley, S., Auman, H., Newcomb, L. F., Boyer, H. D., … Brooks, J. D. (2016). Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 40(11), 1439–56.
- Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study.
  Macleod, L. C., Ellis, W. J., Newcomb, L. F., Zheng, Y., Brooks, J. D., Carroll, P. R., … Lin, D. W. (2016). Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. Journal of Urology.
- MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study
  Eminaga, O., Wei, W., Hawley, S. J., Auman, H., Newcomb, L. F., Simko, J., … Brooks, J. D. (2016). MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLOS ONE, 11(11).
- Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
  Lin, D. W., Newcomb, L. F., Brown, M. D., Sjoberg, D. D., Dong, Y., Brooks, J. D., … Zheng, Y. (2016). Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. European Urology.
- Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids
  Banerjee, S., Zare, R. N., Tibshirani, R. J., Kunder, C. A., Nolley, R., Fan, R., … Sonn, G. A. (2017). Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 114(13), 3334–39.
- NUSAP1 promotes invasion and metastasis of prostate cancer
  Gordon, C. A., Gong, X., Ganesh, D., & Brooks, J. D. (2017). NUSAP1 promotes invasion and metastasis of prostate cancer. ONCOTARGET, 8(18), 29935–50.
- Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns
  Kirby, M. K., Ramaker, R. C., Roberts, B. S., Lasseigne, B. N., Gunther, D. S., Burwell, T. C., … Myers, R. M. (2017). Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns. BMC CANCER, 17.
- Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer
  Gong, X., Siprashvili, Z., Eminaga, O., Shen, Z., Sato, Y., Kume, H., … Brooks, J. D. (2017). Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer. ONCOTARGET, 8(12), 18657–69.
- Contemporary Use of Partial Nephrectomy: Are Older Patients With Impaired Kidney Function Being Left Behind?
  Leppert, J. T., Mittakanti, H. R., Thomas, I.-C., Lamberts, R. W., Sonn, G. A., Chung, B. I., … Brooks, J. D. (2017). Contemporary Use of Partial Nephrectomy: Are Older Patients With Impaired Kidney Function Being Left Behind? UROLOGY, 100, 65–71.
- Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study
  Macleod, L. C., Ellis, W. J., Newcomb, L. F., Zheng, Y., Brooks, J. D., Carroll, P. R., … Lin, D. W. (2017). Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. JOURNAL OF UROLOGY, 197(4), 1026–33.
- Incident CKD after Radical or Partial Nephrectomy.
  Leppert, J. T., Lamberts, R. W., Thomas, I.-C. C., Chung, B. I., Sonn, G. A., Skinner, E. C., … Brooks, J. D. (2017). Incident CKD after Radical or Partial Nephrectomy. Journal of the American Society of Nephrology : JASN.
- Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States.
  Loft, M. D., Berg, K. D., Kjaer, A., Iversen, P., Ferrari, M., Zhang, C. A., … Roder, M. A. (2017). Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. Clinical Genitourinary Cancer.
- Male infertility is associated with altered treatment course of men with cancer.
  Eminaga, O., Li, S., Baker, L. C., Brooks, J. D., & Eisenberg, M. L. (2018). Male infertility is associated with altered treatment course of men with cancer. Andrology.
- Identification of transcripts associated with renal damage due to ureteral obstruction as candidate urinary biomarkers.
  Wu, B., Gong, X., Kennedy, W. A., & Brooks, J. D. (2018). Identification of transcripts associated with renal damage due to ureteral obstruction as candidate urinary biomarkers. American Journal of Physiology. Renal Physiology.
- The Research Implications of PSA Registry Errors: Data from the Veterans Health Administration.
  Guo, D. P., Thomas, I.-C., Mittakanti, H. R., Shelton, J. B., Makarov, D. V., Skolarus, T. A., … Leppert, J. T. (2018). The Research Implications of PSA Registry Errors: Data from the Veterans Health Administration. The Journal of Urology.
- INCREASED EXPRESSION OF NUSAP GENE IN RECURRENT PROSTATE CANCER IS MEDIATED BY E2F
  Gulzar, Z., & Brooks, J. (2011). INCREASED EXPRESSION OF NUSAP GENE IN RECURRENT PROSTATE CANCER IS MEDIATED BY E2F. JOURNAL OF UROLOGY, 185(4), E647.
- Prognostic significance of vascular invasion: A long-term follow-up of 621 radical prostatectomy patients
  Ferrari, M. K., Malhotra, S. M., McNeal, J. E., & Brooks, J. D. (2004). Prognostic significance of vascular invasion: A long-term follow-up of 621 radical prostatectomy patients. JOURNAL OF UROLOGY, 171(4), 222.
- In-depth quantitative analysis of protein glycoforms in human prostate cancer plasma
  Totten, S. M., Kulloli, M., Tanimoto, C., Brooks, J. D., & Pitteri, S. J. (2015). In-depth quantitative analysis of protein glycoforms in human prostate cancer plasma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Liquid biopsy-based assays to monitor residual disease in cancer.
  Mei, G., Sebisanovic, D., Mir, A., Gulzar, Z., Brooks, J. D., Jeffrey, S. S., & Talasaz, A. A. (2013). Liquid biopsy-based assays to monitor residual disease in cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(15).
- Urinary TMPRSS2: Use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance cohort-Results from the Canary/EDRN Prostate Active Surveillance Study
  Lin, D. W., Newcomb, L. F., Brown, E. C., Brooks, J. D., Carroll, P., Feng, Z., … Nelson, P. (2012). Urinary TMPRSS2: Use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance cohort-Results from the Canary/EDRN Prostate Active Surveillance Study. JOURNAL OF CLINICAL ONCOLOGY, 30(5).
- Use of nano-immuno assay to generate rapid, quantitative nanoscale proteomic profiling of the hypoxia pathway in renal cell carcinoma clinical specimens.
  Fan, A. C., Banerjee, P., Leppert, J., Harshman, L. C., Sabatti, C., Brooks, J. D., & Felsher, D. W. (2012). Use of nano-immuno assay to generate rapid, quantitative nanoscale proteomic profiling of the hypoxia pathway in renal cell carcinoma clinical specimens. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Ten-core systematic biopsy results are the most powerful predictors of cancer volume at radical prostatectomy
  Presti, J. C., Brooks, J. D., Gill, H., Nolley, R., & McNeal, J. E. (2002). Ten-core systematic biopsy results are the most powerful predictors of cancer volume at radical prostatectomy. JOURNAL OF UROLOGY, 167(4), 226.
- Treatment and mortality in men with localized prostate cancer: A population-based study in California
  Sieh, W., Lichtensztajn, D. Y., Nelson, D. O., Cockburn, M., West, D. W., Brooks, J. D., & Chang, E. T. (2012). Treatment and mortality in men with localized prostate cancer: A population-based study in California. CANCER RESEARCH, 72.
- The application of genomic and proteomic approaches to human prostate cancer in developing diagnostic and prognostic markers
  Brooks, J. D. (2006). The application of genomic and proteomic approaches to human prostate cancer in developing diagnostic and prognostic markers. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 24(3), 222–23.
- Transcriptome sequencing of circulating tumor cells reveals their heterogeneity
  Cann, G., Gulzar, Z., Tat, M., Li, R., Stuart, S., Khrebtukova, I., … Talasaz, A. A. H. (2011). Transcriptome sequencing of circulating tumor cells reveals their heterogeneity. CANCER RESEARCH, 71.
- PROSTATE CANCER YIELD IN MRI LESIONS VARIES ACROSS RADIOLOGISTS
  Sonn, G., Fan, R., Li, S., Ghanouni, P., Loening, A., Daniel, B., … Brooks, J. (2016). PROSTATE CANCER YIELD IN MRI LESIONS VARIES ACROSS RADIOLOGISTS. JOURNAL OF UROLOGY. ELSEVIER SCIENCE INC.
- S100p: A marker for transitional epithelium and urothelial carcinoma
  Higgins, J. P., Kaygusuz, G., Wang, L., Montgomery, K., Mason, Brooks, J. D., & van de Rijn, M. (2006). S100p: A marker for transitional epithelium and urothelial carcinoma. MODERN PATHOLOGY, 19, 142A.
- Natural history of positive urinary cytology after radical cystectomy - Editorial comment
  Brooks, J. D. (2006). Natural history of positive urinary cytology after radical cystectomy - Editorial comment. JOURNAL OF UROLOGY, 176(5), 2005.
- Evaluation of Putative Renal Cell Carcinoma Markers PAX-2, PAX-8, and hKIM-1 in Germ Cell Tumors (GCT): A Tissue Microarray Study of 100 Cases
  Sangoi, A., Higgins, J., Brooks, J., Bonventre, J., & McKenney, I. (2011). Evaluation of Putative Renal Cell Carcinoma Markers PAX-2, PAX-8, and hKIM-1 in Germ Cell Tumors (GCT): A Tissue Microarray Study of 100 Cases. LABORATORY INVESTIGATION, 91, 222A.
- NANO-SCALE PROTEOMIC PROFILING TO DEFINE DIAGNOSTIC SIGNATURES AND BIOMARKERS OF THERAPEUTIC ACTIVITY IN RCC
  Leppert, J., Fan, A., Liliental, J., Xu, L., Thong, A., Yost, C., … Felsher, D. (2013). NANO-SCALE PROTEOMIC PROFILING TO DEFINE DIAGNOSTIC SIGNATURES AND BIOMARKERS OF THERAPEUTIC ACTIVITY IN RCC. JOURNAL OF UROLOGY. ELSEVIER SCIENCE INC.
- Male pelvic anatomy reconstructed from the visible human data set
  Brooks, J. D., Chao, W. M., & Kerr, J. (1998). Male pelvic anatomy reconstructed from the visible human data set. JOURNAL OF UROLOGY, 159(5), 14.
- INTRA-TUMOR HETEROGENEITY IN RENAL CELL CARCINOMA: IMPLICATIONS FOR PROTEOMIC ANALYSIS OF RENAL MASS BIOPSIES
  Massoudi, R., Hoerner, C., Metzner, T., O'Rourke, J., Curtis, R., Stell, L., … Leppert, J. (2017). INTRA-TUMOR HETEROGENEITY IN RENAL CELL CARCINOMA: IMPLICATIONS FOR PROTEOMIC ANALYSIS OF RENAL MASS BIOPSIES. JOURNAL OF UROLOGY. ELSEVIER SCIENCE INC.
- PTEN Status Determination in Prostate Cancer: Comparison of IHC and FISH in a Large Multi-Center Cohort
  Lotan, T., Moray, C., Wei, W., Troyer, D., Jamaspishvili, T., McKenney, J., … Squire, J. (2015). PTEN Status Determination in Prostate Cancer: Comparison of IHC and FISH in a Large Multi-Center Cohort. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP.
- Measurement of urinary incontinence after prostate surgery from data-mining electronic health records (EHR).
  Hernandez-Boussard, T., Tamang, S., Brooks, J. D., Blayney, D. W., & Shah, N. (2014). Measurement of urinary incontinence after prostate surgery from data-mining electronic health records (EHR). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- The impact of reducing the frequency of prostate specific antigen (PSA) testing among men on active surveillance for prostate cancer
  Cooperberg, M. R., Newcomb, L. F., Brown, E. C., Zhao, S., Feng, Z., Brooks, J. D., & Lin, D. W. (2013). The impact of reducing the frequency of prostate specific antigen (PSA) testing among men on active surveillance for prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(15).
- Nano-scale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC
  Leppert, J. T., Fan, A. C., Metzner, T., Liliental, J. E., Xu, L., Thong, A. E., … Felsher, D. W. (2013). Nano-scale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC. BJU INTERNATIONAL. WILEY-BLACKWELL.
- Normal body mass index is associated with a higher prostate cancer detection rate and less favorable pathologic features in a biopsy population
  Presti, J. C., Lee, U., Brooks, J. D., & Terris, M. K. (2004). Normal body mass index is associated with a higher prostate cancer detection rate and less favorable pathologic features in a biopsy population. JOURNAL OF UROLOGY, 171(4), 122.
- Evaluation of SF-1 Expression in Testicular Germ Cell Tumors: A Tissue Microarray Study of 100 Cases
  Sangoi, A. R., McKenney, J. K., Brooks, J. D., & Higgins, J. P. (2012). Evaluation of SF-1 Expression in Testicular Germ Cell Tumors: A Tissue Microarray Study of 100 Cases. AMERICAN JOURNAL OF CLINICAL PATHOLOGY. OXFORD UNIV PRESS INC.
- Editorial comments
  Brooks, J. D. (2007). Editorial comments. JOURNAL OF UROLOGY, 178(6), 2400.
- Do cancer index and tumor volume predict prostate cancer specific death?
  Tarin, T. V., Chung, B. I., & Brooks, J. D. (2008). Do cancer index and tumor volume predict prostate cancer specific death? JOURNAL OF UROLOGY, 179(4), 115.
- Gene expression in the normal adult human kidney assessed by complementary DNA microarray
  Higgins, J. P., Wang, L., Kambham, N., Montgomery, K., Vogelmann, S., Lemley, K., … Brooks, J. D. (2003). Gene expression in the normal adult human kidney assessed by complementary DNA microarray. MODERN PATHOLOGY, 16(1), 266A.
- Gene expression profiles in renal cell carcinoma assessed by complementary DNA microarray
  Higgins, J. P., Shinghal, R., Reese, J. H., Terris, M., Cohen, R. J., Tibshirani, R., … Brooks, J. D. (2002). Gene expression profiles in renal cell carcinoma assessed by complementary DNA microarray. MODERN PATHOLOGY, 15(1), 164A.
- Gene expression profiles in renal cell carcinoma assessed by complementary DNA microarray
  Higgins, J. P., Shinghal, R., Reese, J. H., Terris, M., Cohen, R. J., Tibshirani, R., … Brooks, J. D. (2002). Gene expression profiles in renal cell carcinoma assessed by complementary DNA microarray. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP.
- Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera.
  Totten, S. M., Adusumilli, R., Kullolli, M., Tanimoto, C., Brooks, J. D., Mallick, P., & Pitteri, S. J. (2018). Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera. Scientific Reports, 8(1), 6509.
- Mining Electronic Health Records to Extract Patient-Centered Outcomes Following Prostate Cancer Treatment.
  Hernandez-Boussard, T., Kourdis, P. D., Seto, T., Ferrari, M., Blayney, D. W., Rubin, D., & Brooks, J. D. (2017). Mining Electronic Health Records to Extract Patient-Centered Outcomes Following Prostate Cancer Treatment. AMIA ... Annual Symposium Proceedings. AMIA Symposium, 2017, 876–82.
- Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study
  Kearns, J. T., Faino, A. V., Newcomb, L. F., Brooks, J. D., Carroll, P. R., Dash, A., … Lin, D. W. (2018). Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. EUROPEAN UROLOGY, 73(5), 706–12.
- Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance
  Jeon, H. G., Yoo, J. H., Jeong, B. C., Seo, S. I., Jeon, S. S., Choi, H.-Y., … Chung, B. I. (2017). Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance. PLOS ONE, 12(11).
- NuSAP is regulated by RB1 and modulates prostate cancer progression
  Gordon, C. A., Gong, X., Gulzar, Z. G., & Brooks, J. D. (2013). NuSAP is regulated by RB1 and modulates prostate cancer progression. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Klip1 lincRNA is a prognostic biomarker for clear cell renal cell carcinoma
  Gong, X., Pollack, J., & Brooks, J. D. (2015). Klip1 lincRNA is a prognostic biomarker for clear cell renal cell carcinoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Mass spectrometric imaging of prostate biopsy samples: Cancer margin assessment from the distribution of small metabolites and lipids
  Banerjee, S., Zare, R. N., Tibshirani, R., Kunder, C., Nolley, R., Fan, R., … Sonn, G. (2017). Mass spectrometric imaging of prostate biopsy samples: Cancer margin assessment from the distribution of small metabolites and lipids. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. AMER CHEMICAL SOC.
- Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.01.043.
  Leppert, J. T., & Brooks, J. D. (2018). Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.01.043. European Urology.
- Trends in Incidence and 5-Year Mortality in Men With Newly Diagnosed, Metastatic Prostate Cancer-A Population-Based Analysis of 2 National Cohorts
  Helgstrand, J. T., Roder, M. A., Klemann, N., Toft, B. G., Lichtensztajn, D. Y., Brooks, J. D., … Iversen, P. (2018). Trends in Incidence and 5-Year Mortality in Men With Newly Diagnosed, Metastatic Prostate Cancer-A Population-Based Analysis of 2 National Cohorts. CANCER, 124(14), 2931–38.
- Validation of Reactive Stroma as an Adverse Prognostic Factor for Gleason Grade 3+3=6 and 3+4=7 Prostatic Adenocarcinomas (PCA) In the Canary Retrospective Radical Prostatectomy (RP) Cohort
  McKenney, J. K., Wei, W., Hawley, S. J., Auman, H., Newcomb, L., Boyer, H., … Brooks, J. D. (2016). Validation of Reactive Stroma as an Adverse Prognostic Factor for Gleason Grade 3+3=6 and 3+4=7 Prostatic Adenocarcinomas (PCA) In the Canary Retrospective Radical Prostatectomy (RP) Cohort. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP.
- Validation of Reactive Stroma as an Adverse Prognostic Factor for Gleason Grade 3+3=6 and 3+4=7 Prostatic Adenocarcinomas (PCA) In the Canary Retrospective Radical Prostatectomy (RP) Cohort
  McKenney, J. K., Wei, W., Hawley, S. J., Auman, H., Newcomb, L., Boyer, H., … Brooks, J. D. (2016). Validation of Reactive Stroma as an Adverse Prognostic Factor for Gleason Grade 3+3=6 and 3+4=7 Prostatic Adenocarcinomas (PCA) In the Canary Retrospective Radical Prostatectomy (RP) Cohort. MODERN PATHOLOGY. NATURE PUBLISHING GROUP.
- PTEN Status Determination in Prostate Cancer: Comparison of IHC and FISH in a Large Multi-Center Cohort
  Lotan, T., Morais, C., Wei, W., Troyer, D., Jamaspishvili, T., Feng, Z., … Squire, J. (2015). PTEN Status Determination in Prostate Cancer: Comparison of IHC and FISH in a Large Multi-Center Cohort. MODERN PATHOLOGY. NATURE PUBLISHING GROUP.
- Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes
  Cooperberg, M. R., Brooks, J. D., Faino, A., Newcomb, L. F., Kearns, J. T., Carroll, P. R., … Zheng, Y. (2018). Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. EUROPEAN UROLOGY, 74(2), 211–17.
- The Role of DNA Methylation in Renal Cell Carcinoma
  Lasseigne, B. N., & Brooks, J. D. (2018). The Role of DNA Methylation in Renal Cell Carcinoma. MOLECULAR DIAGNOSIS & THERAPY, 22(4), 431–42.
- Association of declining PSA values with a lower risk of progression in the Canary Prostate Cancer Active Surveillance Study (PASS)
  Brooks, J. D., Brown, E. C., Cooperberg, M. R., Newcomb, L. F., Carroll, P., Feng, Z., … Lin, D. W. (2013). Association of declining PSA values with a lower risk of progression in the Canary Prostate Cancer Active Surveillance Study (PASS). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Architecture and Implementation of a Clinical Research Data Warehouse for Prostate Cancer.
  Seneviratne, M. G., Seto, T., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2018). Architecture and Implementation of a Clinical Research Data Warehouse for Prostate Cancer. EGEMS (Washington, DC), 6(1), 13.
- Defining new drivers of castration- resistant prostate cancer
  Hsu, E.-chi, Rice, M., Nolley, R., Bermudez, A., Huang, J., Peehl, D., … Stoyanova, T. (2018). Defining new drivers of castration- resistant prostate cancer. CANCER RESEARCH, 78(16), 90.
- Methionine aminopeptidase II (MetAP2) activated in situ self-assembly of small-molecule probes for imaging prostate cancer.
  Xie, J., Rice, M., Cheng, Y., Song, G., Kunder, C., Brooks, J. D., … Rao, J. (2018). Methionine aminopeptidase II (MetAP2) activated in situ self-assembly of small-molecule probes for imaging prostate cancer. CANCER RESEARCH, 78(16), 115–16.
- VASECTOMY AND THE RISK OF PROSTATE CANCER IN A PROSPECTIVE US COHORT: ANALYSIS IN THE PRESENCE OF SELECTION BIAS
  Davenport, M., Li, S., Brooks, J., Cullen, M., & Eisenberg, M. (2016). VASECTOMY AND THE RISK OF PROSTATE CANCER IN A PROSPECTIVE US COHORT: ANALYSIS IN THE PRESENCE OF SELECTION BIAS. JOURNAL OF UROLOGY. ELSEVIER SCIENCE INC.
- The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
  Roder, M. A., Berg, K. D., Loft, M. D., Thomsen, F. B., Ferrari, M., Kurbegovic, S., … Iversen, P. (2018). The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy. European Urology Focus, 4(3), 360–68.
- James D. Brooks: prostate cancer screening awaits optimization to reduce inappropriate treatment
  Li, B., & Brooks, J. D. (2018). James D. Brooks: prostate cancer screening awaits optimization to reduce inappropriate treatment. TRANSLATIONAL ANDROLOGY AND UROLOGY, 7(5), 903–6.
- PREOPERATIVE KIDNEY FUNCTION TRENDS: IMPROVING ESTIMATES OF BASELINE KIDNEY FUNCTION PRIOR TO KIDNEY CANCER SURGERY
  Sun, A., Thomas, C., Ganesan, C., Sylman, J., Pao, A., Wagner, T., … Leppert, J. (2018). PREOPERATIVE KIDNEY FUNCTION TRENDS: IMPROVING ESTIMATES OF BASELINE KIDNEY FUNCTION PRIOR TO KIDNEY CANCER SURGERY. JOURNAL OF UROLOGY, 199(4), E362.
- Elevated urinary lipocalin-2, interleukin-6 and monocyte chemoattractant protein-1 levels in children with congenital ureteropelvic junction obstruction.
  Yu, L., Zhou, L., Li, Q., Li, S., Luo, X., Zhang, C., … Sun, H. (2018). Elevated urinary lipocalin-2, interleukin-6 and monocyte chemoattractant protein-1 levels in children with congenital ureteropelvic junction obstruction. Journal of Pediatric Urology.
- Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.
  Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Shah, S. A., Sieh, W., Chung, B. I., … Cheng, I. (2018). Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population. Journal of the National Comprehensive Cancer Network : JNCCN, 16(11), 1353–60.
- Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer.
  Seneviratne, M. G., Bozkurt, S., Patel, M. I., Seto, T., Brooks, J. D., Blayney, D. W., … Hernandez-Boussard, T. (2018). Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. Cancer.
- Analysis of Released N-Glycans and Glycopeptide Profiling of Prostate Cancer Tissue
  Totten, S. M., Bermudez, A., Guerrero, A., Yan, J., Jones, A., Brooks, J. D., & Pitteri, S. J. (2018). Analysis of Released N-Glycans and Glycopeptide Profiling of Prostate Cancer Tissue. GLYCOBIOLOGY. OXFORD UNIV PRESS INC.
- Continued 5 alpha-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS
  Kearns, J. T., Faino, A., Schenk, J. M., Newcomb, L. F., Brooks, J. D., Carroll, P. R., … Lin, D. W. (2019). Continued 5 alpha-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. JOURNAL OF UROLOGY, 201(1), 106–11.
- An Automated Feature Engineering for Digital Rectal Examination Documentation using Natural Language Processing.
  Bozkurt, S., Park, J. I., Kan, K. M., Ferrari, M., Rubin, D. L., Brooks, J. D., & Hernandez-Boussard, T. (2018). An Automated Feature Engineering for Digital Rectal Examination Documentation using Natural Language Processing. AMIA ... Annual Symposium Proceedings. AMIA Symposium, 2018, 288–94.
- Identifying Cases of Metastatic Prostate Cancer Using Machine Learning on Electronic Health Records.
  Seneviratne, M. G., Banda, J. M., Brooks, J. D., Shah, N. H., & Hernandez-Boussard, T. M. (2018). Identifying Cases of Metastatic Prostate Cancer Using Machine Learning on Electronic Health Records. AMIA ... Annual Symposium Proceedings. AMIA Symposium, 2018, 1498–1504.
- Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC
  Fan, A. C., Leppert, J., Liliental, J. E., Xu, L., Thong, A. E., Yost, C., … Felsher, D. W. (2013). Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Practice-based evidence for factors associated with urinary incontinence following prostate cancer care.
  Li, K., Magnani, C. J., Bozkurt, S., Seto, T., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2018). Practice-based evidence for factors associated with urinary incontinence following prostate cancer care. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Utilization of Prostate Cancer Quality Metrics for Research and Quality Improvement: A Structured Review
  Gori, D., Dulal, R., Blayney, D. W., Brooks, J. D., Fantini, M. P., McDonald, K. M., & Hernandez-Boussard, T. (2019). Utilization of Prostate Cancer Quality Metrics for Research and Quality Improvement: A Structured Review. JOINT COMMISSION JOURNAL ON QUALITY AND PATIENT SAFETY, 45(3), 217–26.
- A natural language processing algorithm to measure quality prostate cancer care.
  Hernandez-Boussard, T., Kourdis, P., Dulal, R., Ferrari, M., Henry, S., Seto, T., … Brooks, J. D. (2017). A natural language processing algorithm to measure quality prostate cancer care. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.
  Jeon, H. G., Yoo, J. H., Jeong, B. C., Seo, S. I., Jeon, S. S., Choi, H.-Y. Y., … Chung, B. I. (2017). Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance. PloS One, 12(11), e0186026.
- Performance of multiparametric MRI appears better when measured in patients who undergo radical prostatectomy.
  Wang, N. N., Fan, R. E., Leppert, J. T., Ghanouni, P., Kunder, C. A., Brooks, J. D., … Sonn, G. A. (2018). Performance of multiparametric MRI appears better when measured in patients who undergo radical prostatectomy. Research and Reports in Urology, 10, 233–235.
- Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.
  Sahoo, D., Wei, W., Auman, H., Hurtado-Coll, A., Carroll, P. R., Fazli, L., … Brooks, J. D. (2018). Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. Oncotarget, 9(5), 6550–61.
- PIVOT and the challenges of localized prostate cancer care.
  Weinberg, A. E., & Brooks, J. D. (2012). PIVOT and the challenges of localized prostate cancer care. Translational Andrology and Urology, 1(3), 141–3.
- Weakly supervised natural language processing for assessing patient-centered outcome following prostate cancer treatment.
  Banerjee, I., Li, K., Seneviratne, M., Ferrari, M., Seto, T., Brooks, J. D., … Hemandez-Boussard, T. (2019). Weakly supervised natural language processing for assessing patient-centered outcome following prostate cancer treatment. JAMIA Open, 2(1), 150–59.
- Vasectomy and the risk of prostate cancer in a prospective US Cohort: Data from the NIH-AARP Diet and Health Study
  Davenport, M. T., Zhang, C. A., Leppert, J. T., Brooks, J. D., & Eisenberg, M. L. (2019). Vasectomy and the risk of prostate cancer in a prospective US Cohort: Data from the NIH-AARP Diet and Health Study. ANDROLOGY, 7(2), 178–83.
- Applying the PRECISION approach in biopsy naïve and previously negative prostate biopsy patients.
  Wang, N. N., Teslovich, N. C., Fan, R. E., Ghanouni, P., Leppert, J. T., Brooks, J. D., … Sonn, G. A. (2019). Applying the PRECISION approach in biopsy naïve and previously negative prostate biopsy patients. Urologic Oncology.
- Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis.
  Middleton, L. W., Shen, Z., Varma, S., Pollack, A. S., Gong, X., Zhu, S., … Pollack, J. R. (2019). Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis. JCI Insight, 5.
- N-linked glycosylation site mapping in prostate cancer and matched normal tissue: Defining glycan microheterogeneity
  Totten, S. M., Tanimoto, C., Bermudez, A., Hembree, A., Brooks, J. D., & Pitteri, S. J. (2018). N-linked glycosylation site mapping in prostate cancer and matched normal tissue: Defining glycan microheterogeneity. CANCER RESEARCH, 78(13).
- PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.
  Magnani, C. J., Li, K., Seto, T., McDonald, K. M., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2019). PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes. Journal of the National Comprehensive Cancer Network : JNCCN, 17(7), 795–803.
- Is it possible to automatically assess pretreatment digital rectal examination documentation using natural language processing? A single-centre retrospective study.
  Bozkurt, S., Kan, K. M., Ferrari, M. K., Rubin, D. L., Blayney, D. W., Hernandez-Boussard, T., & Brooks, J. D. (2019). Is it possible to automatically assess pretreatment digital rectal examination documentation using natural language processing? A single-centre retrospective study. BMJ Open, 9(7), e027182.
- Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis.
  Kristensen, G., Berg, K. D., Toft, B. G., Stroomberg, H. V., Nolley, R., Brooks, J. D., … Roder, M. A. (2019). Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis. Journal of Clinical Pathology.
- Early detection of unilateral ureteral obstruction by desorption electrospray ionization mass spectrometry.
  Banerjee, S., Wong, A. C.-Y., Yan, X., Wu, B., Zhao, H., Tibshirani, R. J., … Brooks, J. D. (2019). Early detection of unilateral ureteral obstruction by desorption electrospray ionization mass spectrometry. Scientific Reports, 9(1), 11007.
- AUTOMATED DETECTION OF PROSTATE CANCER ON MULTIPARAMETRIC MRI USING DEEP NEURAL NETWORKS TRAINED ON SPATIAL COORDINATES AND PATHOLOGY OF BIOPSY CORES
  Chen, L., Bien, N., Fan, R., Cheong, R., Rajpurkar, P., Thong, A., … Sonn, G. (2019). AUTOMATED DETECTION OF PROSTATE CANCER ON MULTIPARAMETRIC MRI USING DEEP NEURAL NETWORKS TRAINED ON SPATIAL COORDINATES AND PATHOLOGY OF BIOPSY CORES. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-C-13]-ketoisocaproate
  Billingsley, K. L., Park, J. M., Josan, S., Hurd, R., Mayer, D., Spielman-Sun, E., … Spielman, D. (2014). The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-C-13]-ketoisocaproate. MAGNETIC RESONANCE IMAGING, 32(7), 791–95.
- Distribution of Global Health Measures From Routinely Collected PROMIS Surveys in Patients With Breast Cancer or Prostate Cancer
  Seneviratne, M. G., Bozkurt, S., Patel, M., Seto, T., Brooks, J. D., Blayney, D. W., … Hernandez-Boussard, T. (2019). Distribution of Global Health Measures From Routinely Collected PROMIS Surveys in Patients With Breast Cancer or Prostate Cancer. CANCER, 125(6), 943–51.
- Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies.
  Xu, L., Lee, J.-R., Hao, S., Ling, X. B., Brooks, J. D., Wang, S. X., & Gambhir, S. S. (2019). Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies. PloS One, 14(8), e0221051.
- Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma.
  Hoerner, C. R., Massoudi, R., Metzner, T. J., Stell, L., O'Rourke, J. J., Kong, C. S., … Fan, A. C. (2018). Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma. European Urology Oncology.
- Machine Learning Approaches for Extracting Stage from Pathology Reports in Prostate Cancer.
  Lenain, R., Seneviratne, M. G., Bozkurt, S., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2019). Machine Learning Approaches for Extracting Stage from Pathology Reports in Prostate Cancer. Studies in Health Technology and Informatics, 264, 1522–23.
- Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)
  Newcomb, L. F., Zheng, Y., Faino, A., Bianchi-Frias, D., Cooperberg, M. R., Brown, M. D., … Lin, D. W. (2019). Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). PROSTATE CANCER AND PROSTATIC DISEASES, 22(3), 438–45.
- Simultaneous transrectal ultrasound and photoacoustic human prostate imaging.
  Kothapalli, S.-R., Sonn, G. A., Choe, J. W., Nikoozadeh, A., Bhuyan, A., Park, K. K., … Gambhir, S. S. (2019). Simultaneous transrectal ultrasound and photoacoustic human prostate imaging. Science Translational Medicine, 11(507).
- Framework for the co-registration of MRI and Histology Images in Prostate Cancer Patients with Radical Prostatectomy
  Rusu, M., Kunder, C., Fan, R., Ghanouni, P., West, R., Sonn, G., & Brooks, J. (2019). Framework for the co-registration of MRI and Histology Images in Prostate Cancer Patients with Radical Prostatectomy. MEDICAL IMAGING 2019: IMAGE PROCESSING, 10949.
- Extracting Patient-Centered Outcomes from Clinical Notes in Electronic Health Records: Assessment of Urinary Incontinence After Radical Prostatectomy.
  Gori, D., Banerjee, I., Chung, B. I., Ferrari, M., Rucci, P., Blayney, D. W., … Hernandez-Boussard, T. (2019). Extracting Patient-Centered Outcomes from Clinical Notes in Electronic Health Records: Assessment of Urinary Incontinence After Radical Prostatectomy. EGEMS (Washington, DC), 7(1), 43.
- Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists
  Sonn, G. A., Fan, R. E., Ghanouni, P., Wang, N. N., Brooks, J. D., Loening, A. M., … Leppert, J. T. (2019). Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. EUROPEAN UROLOGY FOCUS, 5(4), 592–99.
- S100A10 is a critical mediator of GAS6/AXL-induced angiogenesis in renal cell carcinoma.
  Xiao, Y., Zhao, H., Tian, L., Nolley, R., Diep, A. N., Ernst, A., … Rankin, E. B. (2019). S100A10 is a critical mediator of GAS6/AXL-induced angiogenesis in renal cell carcinoma. Cancer Research.
- Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS).
  Lin, D. W., Zheng, Y., McKenney, J., Brown, M., Lu, R., Crager, M., … Newcomb, L. F. (2019). Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS). JOURNAL OF CLINICAL ONCOLOGY, 37(7).
- African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study (PASS).
  Schenk, J. M., Newcomb, L. F., Zheng, Y., Faino, A. V., Zhu, K., Nyame, Y. A., … Lin, D. W. (2019). African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study (PASS). The Journal of Urology, 101097JU0000000000000621.
- Editorial Comment.
  Brooks, J. D. (2019). Editorial Comment. The Journal of Urology, 10109701JU00006126127033813.
- miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma.
  Gong, X., Zhao, H., Saar, M., Peehl, D. M., & Brooks, J. D. (2019). miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer, 3(2), 119–32.
- Identification of Diagnostic Metabolic Signatures in Clear Cell Renal Cell Carcinoma Using Mass Spectrometry Imaging.
  Vijayalakshmi, K., Shankar, V., Bain, R. M., Nolley, R., Sonn, G. A., Kao, C.-S., … Brooks, J. D. (2019). Identification of Diagnostic Metabolic Signatures in Clear Cell Renal Cell Carcinoma Using Mass Spectrometry Imaging. International Journal of Cancer.
- Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
  Hsu, E.-C. C., Rice, M. A., Bermudez, A., Marques, F. J., Aslan, M., Liu, S., … Stoyanova, T. (2020). Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proceedings of the National Academy of Sciences of the United States of America.
- Reply by Authors.
  Schenk, J. M., Newcomb, L. F., Zheng, Y., Faino, A. V., Zhu, K., Nyame, Y. A., … Lin, D. W. (2020). Reply by Authors. The Journal of Urology, 101097JU000000000000062102.
- Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer
  Li, K., Banerjee, I., Magnani, C. J., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2020). Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer. RESEARCH AND REPORTS IN UROLOGY, 12, 7–14.
- Leveraging Digital Data to Inform and Improve Quality Cancer Care.
  Hernandez-Boussard, T., Blayney, D. W., & Brooks, J. D. (2020). Leveraging Digital Data to Inform and Improve Quality Cancer Care. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology.
- The Urine Albumin-Creatinine Ratio and Kidney Function after Nephrectomy.
  Sun, A. J., Thomas, I.-C., Velaer, K. N., Ganesan, C., Song, S., Pao, A. C., … Leppert, J. T. (2020). The Urine Albumin-Creatinine Ratio and Kidney Function after Nephrectomy. The Journal of Urology, 101097JU0000000000001005.
- 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort.
  Lin, D. W., Zheng, Y., McKenney, J. K., Brown, M. D., Lu, R., Crager, M., … Newcomb, L. F. (2020). 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1902267.
- Characterization of the mTOR autophosphorylation site, S2481, as a novel biomarker in renal cell carcinoma (RCC)
  Harshman, L. C., Muller, K., Lin, C.-D., Brooks, J. D., Higgins, J., Berglin, J., … Copp, J. (2014). Characterization of the mTOR autophosphorylation site, S2481, as a novel biomarker in renal cell carcinoma (RCC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma
  Williams, A. A., Higgins, J. P. T., Zhao, H., Ljungberg, B., & Brooks, J. D. (2009). CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC CLINICAL PATHOLOGY, 9.
- The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.
  Rozenblatt-Rosen, O., Regev, A., Oberdoerffer, P., Nawy, T., Hupalowska, A., Rood, J. E., … Williams, E. H. (2020). The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 181(2), 236–49.
- Comparison of orthogonal NLP methods for clinical phenotyping and assessment of bone scan utilization among prostate cancer patients
  Coquet, J., Bozkurt, S., Kan, K. M., Ferrari, M. K., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2019). Comparison of orthogonal NLP methods for clinical phenotyping and assessment of bone scan utilization among prostate cancer patients. JOURNAL OF BIOMEDICAL INFORMATICS, 94.
- Magnetic Resonance Imaging for the Detection of High-Grade Cancer in the Canary Prostate Active Surveillance Study.
  Liss, M. A., Newcomb, L. F., Zheng, Y., Garcia, M. P., Filson, C. P., Boyer, H., … Lin, D. W. (2020). Magnetic Resonance Imaging for the Detection of High-Grade Cancer in the Canary Prostate Active Surveillance Study. The Journal of Urology, 101097JU0000000000001088.
- Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California.
  DeRouen, M. C., McKinley, M., Shah, S. A., Borno, H. T., Aoki, R., Lichtensztajn, D. Y., … Cheng, I. (2020). Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California. Cancer Causes & Control : CCC.
- Registration of pre-surgical MRI and histopathology images from radical prostatectomy via RAPSODI.
  Rusu, M., Shao, W., Kunder, C. A., Wang, J. B., Soerensen, S. J., Teslovich, N. C., … Sonn, G. A. (2020). Registration of pre-surgical MRI and histopathology images from radical prostatectomy via RAPSODI. Medical Physics.
- Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration.
  Sohlberg, E. M., Thomas, I.-C., Yang, J., Kapphahn, K., Daskivich, T. J., Skolarus, T. A., … Leppert, J. T. (2020). Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration. Urologic Oncology.
- Phenotyping severity of patient-centered outcomes using clinical notes: A prostate cancer use case
  Bozkurt, S., Paul, R., Coquet, J., Sun, R., Banerjee, I., Brooks, J. D., & Hernandez-Boussard, T. (2020). Phenotyping severity of patient-centered outcomes using clinical notes: A prostate cancer use case. LEARNING HEALTH SYSTEMS.
- AZGP1 Protein Expression in Hormone-Naive Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy.
  Winther, M. D., Kristensen, G., Stroomberg, H. V., Berg, K. D., Toft, B. G., Brooks, J. D., … Roder, M. A. (2020). AZGP1 Protein Expression in Hormone-Naive Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy. Diagnostics (Basel, Switzerland), 10(8).
- The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor.
  Xiao, Y., Thakkar, K. N., Zhao, H., Broughton, J., Li, Y., Seoane, J. A., … Rankin, E. B. (2020). The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America.
- MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING AND RECLASSIFICATION FROM ACTIVE SURVEILLANCE
  Magnani, C. J., Bievre, N., Erdogdu, B., Baker, L. C., Brooks, J. D., & Hernandez-Boussard, T. (2020). MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING AND RECLASSIFICATION FROM ACTIVE SURVEILLANCE. JOURNAL OF UROLOGY, 203, E342–E343.
- Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
  Cooperberg, M. R., Zheng, Y., Faino, A. V., Newcomb, L. F., Zhu, K., Cowan, J. E., … Lin, D. W. (2020). Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncology, e203187.
- Early-Life Cardiorespiratory Fitness and Long-Term Risk of Prostate Cancer.
  Crump, C., Stattin, P., Brooks, J. D., Stocks, T., Sundquist, J., Sieh, W., & Sundquist, K. (2020). Early-Life Cardiorespiratory Fitness and Long-Term Risk of Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology.
- Sudden PSA rise to =20 ng/ml and prostate cancer diagnosis in the United States: A population-based study.
  Vilson, F. L., Li, S., Brooks, J. D., & Eisenberg, M. L. (2020). Sudden PSA rise to =20 ng/ml and prostate cancer diagnosis in the United States: A population-based study. The Prostate.
- Association between patient-initiated emails and overall 2-year survival in cancer patients undergoing chemotherapy: Evidence from the real-world setting.
  Coquet, J., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2020). Association between patient-initiated emails and overall 2-year survival in cancer patients undergoing chemotherapy: Evidence from the real-world setting. Cancer Medicine.
- Development of a DNA Methylation-Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma.
  Brennan, K., Metzner, T. J., Kao, C.-S. S., Massie, C. E., Stewart, G. D., Haile, R. W., … Gevaert, O. (2020). Development of a DNA Methylation-Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma. JCO Precision Oncology, 4.
- Sprr2f protects against renal injury by decreasing the level of reactive oxygen species in female mice.
  Huynh, K. M., Wong, A., Wu, B., Horschman, M., Zhao, H., & Brooks, J. D. (2020). Sprr2f protects against renal injury by decreasing the level of reactive oxygen species in female mice. American Journal of Physiology. Renal Physiology.
- Detection of prostate cancer and determination of its significance using explainable artificial intelligence.
  Eminaga, O., Loening, A., Lu, A., Brooks, J. D., & Rubin, D. (2020). Detection of prostate cancer and determination of its significance using explainable artificial intelligence. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Four distinct patient-reported outcome (PRO) trajectories in longitudinal responses collected before, during, and after chemotherapy.
  Blayney, D. W., Azad, A., Yilmaz, M., Bozkurt, S., Brooks, J. D., & Hernandez-Boussard, T. (2020). Four distinct patient-reported outcome (PRO) trajectories in longitudinal responses collected before, during, and after chemotherapy. JOURNAL OF CLINICAL ONCOLOGY, 38(15).
- Clinical Trial Outcomes in Urology: Assessing Early Discontinuation, Results Reporting, and Publication in ClinicalTrials.Gov Registrations 2007-2019.
  Magnani, C. J., Steinberg, J. R., Harmange, C. I., Zhang, X., Driscoll, C., Bell, A., … Brooks, J. D. (2020). Clinical Trial Outcomes in Urology: Assessing Early Discontinuation, Results Reporting, and Publication in ClinicalTrials.Gov Registrations 2007-2019. The Journal of Urology, 101097JU0000000000001432.
- Phenotyping severity of patient-centered outcomes using clinical notes: A prostate cancer use case.
  Bozkurt, S., Paul, R., Coquet, J., Sun, R., Banerjee, I., Brooks, J. D., & Hernandez-Boussard, T. (2020). Phenotyping severity of patient-centered outcomes using clinical notes: A prostate cancer use case. Learning Health Systems, 4(4), e10237.
- Association of renal cell carcinoma subtypes with race/ethnicity and comorbid medical conditions
  Lichtensztajn, D. Y., Hofer, B. M., Leppert, J. T., Brooks, J. D., Chung, B., Shah, S. A., … Cheng, I. (2020). Association of renal cell carcinoma subtypes with race/ethnicity and comorbid medical conditions. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 29(6).
- Testicular cancer in Hispanics: Incidence of subtypes over time according to neighborhood sociodemographic factors in California
  DeRouen, M. C., McKinley, M., Shah, S. A., Borno, H. T., Aoki, R., Lichtensztajn, D. Y., … Cheng, I. (2020). Testicular cancer in Hispanics: Incidence of subtypes over time according to neighborhood sociodemographic factors in California. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 29(6).
- Laboratory-wide association study of survival with prostate cancer.
  Sohlberg, E. M., Thomas, I.-C., Yang, J., Kapphahn, K., Velaer, K. N., Goldstein, M. K., … Leppert, J. T. (2020). Laboratory-wide association study of survival with prostate cancer. Cancer.
- Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer.
  Liu, S., Shen, M., Hsu, E.-C. C., Zhang, C. A., Garcia-Marques, F., Nolley, R., … Stoyanova, T. (2020). Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer. British Journal of Cancer.
- The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration
  Guo, D. P., Thomas, I.-C., Mittakanti, H. R., Shelton, J. B., Makarov, D. V., Skolarus, T. A., … Leppert, J. T. (2018). The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration. JOURNAL OF UROLOGY, 200(3), 541–47.
- Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance.
  Magnani, C. J., Bievre, N., Baker, L. C., Brooks, J. D., Blayney, D. W., & Hernandez-Boussard, T. (2021). Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance. European Urology Open Science, 23, 20–29.
- ProsRegNet: A deep learning framework for registration of MRI and histopathology images of the prostate.
  Shao, W., Banh, L., Kunder, C. A., Fan, R. E., Soerensen, S. J., Wang, J. B., … Rusu, M. (2020). ProsRegNet: A deep learning framework for registration of MRI and histopathology images of the prostate. Medical Image Analysis, 68, 101919.
- Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer.
  Ghoochani, A., Hsu, E.-C. C., Aslan, M., Rice, M. A., Nguyen, H. M., Brooks, J. D., … Stoyanova, T. (2021). Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Research.
- Assessment of a Clinical Trial-Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer.
  Coquet, J., Bievre, N., Billaut, V., Seneviratne, M., Magnani, C. J., Bozkurt, S., … Hernandez-Boussard, T. (2021). Assessment of a Clinical Trial-Derived Survival Model in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 4(1), e2031730.
- 3D Registration of pre-surgical prostate MRI and histopathology images via super-resolution volume reconstruction.
  Sood, R. R., Shao, W., Kunder, C., Teslovich, N. C., Wang, J. B., Soerensen, S. J., … Rusu, M. (2021). 3D Registration of pre-surgical prostate MRI and histopathology images via super-resolution volume reconstruction. Medical Image Analysis, 69, 101957.
- In vivo imaging of methionine aminopeptidase II for prostate cancer risk stratification.
  Xie, J., Rice, M. A., Chen, Z., Cheng, Y., Hsu, E.-C. C., Chen, M., … Rao, J. (2021). In vivo imaging of methionine aminopeptidase II for prostate cancer risk stratification. Cancer Research.
- Determination of biologic and prognostic feature scores from whole slide histology images using deep learning.
  Eminaga, O., Abbas, M., Semjonow, A., Brooks, J. D., & Rubin, D. (2020). Determination of biologic and prognostic feature scores from whole slide histology images using deep learning. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Prevalence of Postprostatectomy Incontinence Requiring Anti-incontinence Surgery After Radical Prostatectomy for Prostate Cancer: A Retrospective Population-Based Analysis.
  Kim, J. H., Jeong, I. G., Khandwala, Y. S., Hernandez-Boussard, T., Brooks, J. D., & Chung, B. I. (2021). Prevalence of Postprostatectomy Incontinence Requiring Anti-incontinence Surgery After Radical Prostatectomy for Prostate Cancer: A Retrospective Population-Based Analysis. International Neurourology Journal.
- Automated Detection of Aggressive and Indolent Prostate Cancer on Magnetic Resonance Imaging.
  Seetharaman, A., Bhattacharya, I., Chen, L. C., Kunder, C. A., Shao, W., Soerensen, S. J., … Rusu, M. (2021). Automated Detection of Aggressive and Indolent Prostate Cancer on Magnetic Resonance Imaging. Medical Physics.
- Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay.
  Liu, S., Garcia-Marques, F., Zhang, C. A., Lee, J. J., Nolley, R., Shen, M., … Stoyanova, T. (2021). Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay. Scientific Reports, 11(1), 7612.
- Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population
  Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Shah, S. A., Sieh, W., Chung, B., … Cheng, I. (2018). Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(11), 1353–1360.
- Re: Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer: authors' reply
  Sieh, W., Lichtensztajn, D. Y., Gomez, S. L., Liu, J.-J., Chung, B. I., Cheng, I., & Brooks, J. D. (2015). Re: Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer: authors' reply. PATHOLOGY, 47(4), 394–395.
- Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer
  Liu, J.-J., Lichtensztajn, D. Y., Gomez, S. L., Sieh, W., Chung, B. I., Cheng, I., & Brooks, J. D. (2014). Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer. PATHOLOGY, 46(4), 306–310.
- Reply to the Editorial Comment on: Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. Urology. 2021.
  Soerensen, S. J., Thomas, I.-C., Schmidt, B., Daskivich, T., Skolarus, T. A., Jackson, C., … Leppert, J. T. (2021). Reply to the Editorial Comment on: Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. Urology. 2021. Urology.
- MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer.
  Hsu, E.-C. C., Shen, M., Aslan, M., Liu, S., Kumar, M., Garcia-Marques, F., … Stoyanova, T. (2021). MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer. Scientific Reports, 11(1), 13305.
- When can active surveillance be less active? Prediction of long-term nonreclassification for men with low-risk prostate cancer.
  Cooperberg, M. R., Faino, A. V., Newcomb, L. F., Carroll, P., Kearns, J. T., Brooks, J. D., … Zheng, Y. (2018). When can active surveillance be less active? Prediction of long-term nonreclassification for men with low-risk prostate cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Diverse patient trajectories during cytotoxic chemotherapy: Capturing longitudinal patient-reported outcomes.
  Azad, A. D., Yilmaz, M., Bozkurt, S., Brooks, J. D., Blayney, D. W., & Hernandez-Boussard, T. (2021). Diverse patient trajectories during cytotoxic chemotherapy: Capturing longitudinal patient-reported outcomes. Cancer Medicine.
- Consumption of cruciferous vegetables and the risk of bladder cancer in a prospective US cohort: data from the NIH-AARP diet and health study
  Nguyen, T. P., Zhang, C. A., Sonn, G. A., Eisenberg, M. L., & Brooks, J. D. (2021). Consumption of cruciferous vegetables and the risk of bladder cancer in a prospective US cohort: data from the NIH-AARP diet and health study. AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 9(3), 229–238.
- Identifying a novel glycolytic inhibitor for treatment of aggressive prostate cancer.
  Stoyanova, T. I., Rice, M. A., Kumar, V., Tailor, D., Garcia-Marques, F. J., Bermudez, A., … Stoyanova, T. (2021). Identifying a novel glycolytic inhibitor for treatment of aggressive prostate cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Trop2 regulates prostate cancer growth and metastasis through distinct molecular mechanisms.
  Stoyanova, T. I., Hsu, E.-C., Liu, S., Marques, F. J. G., Bermudez, A., Aslan, M., … Brooks, J. D. (2021). Trop2 regulates prostate cancer growth and metastasis through distinct molecular mechanisms. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- AUTHOR REPLY.
  Soerensen, S. J., Thomas, I.-C. C., Schmidt, B., Daskivich, T. J., Skolarus, T. A., Jackson, C., … Leppert, J. T. (2021). AUTHOR REPLY. Urology, 155, 76.
- TREATMENT IN THE ABSENCE OF DISEASE RECLASSIFICATION AMONG MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER
  Kirk, P., Newcomb, L., Zhu, K., Zheng, Y., Schenk, J., Lin, D., & Gore, J. (2021). TREATMENT IN THE ABSENCE OF DISEASE RECLASSIFICATION AMONG MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer
  Kirk, P. S., Zhu, K., Zheng, Y., Newcomb, L. F., Schenk, J. M., Brooks, J. D., … Gore, J. L. (2021). Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. CANCER.
- Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS).
  Velaer, K., Thomas, I.-C. C., Yang, J., Kapphahn, K., Metzner, T. J., Golla, A., … Leppert, J. T. (2021). Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS). Urologic Oncology.
- REAL-WORLD VALIDATION AND GENERALIZABILITY OF A PSAK PREDICTION TOOL FOR ACTIVE SURVEILLANCE RECLASSIFICATION
  Magnani, C. J., Moyal, A., Erdogdu, B., Peterson, D. J., Bozkurt, S., Hernandez-Boussard, T., & Brooks, J. D. (2021). REAL-WORLD VALIDATION AND GENERALIZABILITY OF A PSAK PREDICTION TOOL FOR ACTIVE SURVEILLANCE RECLASSIFICATION. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- PROSTERIA: A CLAIMS-BASED STUDY OF DEMOGRAPHIC AND TEMPORAL TRENDS IN FREQUENT PROSTATE SPECIFIC ANTIGEN TESTING
  Peterson, D., Li, S., Bhambhvani, H., Brooks, J., & Eisenberg, M. (2021). PROSTERIA: A CLAIMS-BASED STUDY OF DEMOGRAPHIC AND TEMPORAL TRENDS IN FREQUENT PROSTATE SPECIFIC ANTIGEN TESTING. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Oncogene-mediated metabolic gene signature predicts breast cancer outcome.
  Aslan, M., Hsu, E.-C. C., Garcia-Marques, F. J., Bermudez, A., Liu, S., Shen, M., … Stoyanova, T. (2021). Oncogene-mediated metabolic gene signature predicts breast cancer outcome. NPJ Breast Cancer, 7(1), 141.
- Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort
  Malaret, A. J. W., Chang, P., Newcomb, L., Faino, A., Zheng, Y., Zhu, K., … Wagner, A. A. (2021). Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. UROLOGY PRACTICE, 8(5), 576–582.
- Machine Learning Applied to Electronic Health Records: Identification of Chemotherapy Patients at High Risk for Preventable Emergency Department Visits and Hospital Admissions.
  Peterson, D. J., Ostberg, N. P., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2021). Machine Learning Applied to Electronic Health Records: Identification of Chemotherapy Patients at High Risk for Preventable Emergency Department Visits and Hospital Admissions. JCO Clinical Cancer Informatics, 5, 1106–1126.
- Weakly Supervised Registration of Prostate MRI and Histopathology Images
  Shao, W., Bhattacharya, I., Soerensen, S. J. C., Kunder, C. A., Wang, J. B., Fan, R. E., … Rusu, M. (2021). Weakly Supervised Registration of Prostate MRI and Histopathology Images. MEDICAL IMAGE COMPUTING AND COMPUTER ASSISTED INTERVENTION - MICCAI 2021, PT IV. SPRINGER INTERNATIONAL PUBLISHING AG.
- Weakly supervised natural language processing for assessing patient-centered outcome following prostate cancer treatment
  Banerjee, I., Li, K., Seneviratne, M., Ferrari, M., Seto, T., Brooks, J. D., … Hernandez-Boussard, T. (2019). Weakly supervised natural language processing for assessing patient-centered outcome following prostate cancer treatment. JAMIA OPEN, 2(1), 150–159.
- Selective identification and localization of indolent and aggressive prostate cancers via CorrSigNIA: an MRI-pathology correlation and deep learning framework.
  Bhattacharya, I., Seetharaman, A., Kunder, C., Shao, W., Chen, L. C., Soerensen, S. J., … Rusu, M. (2021). Selective identification and localization of indolent and aggressive prostate cancers via CorrSigNIA: an MRI-pathology correlation and deep learning framework. Medical Image Analysis, 75, 102288.
- Identification of patients at high risk for preventable emergency department visits and inpatient admissions after starting chemotherapy: Machine learning applied to comprehensive electronic health record data.
  Peterson, D. J., Ostberg, N. P., Blayney, D. W., Brooks, J. D., & Hernandez-Boussard, T. (2021). Identification of patients at high risk for preventable emergency department visits and inpatient admissions after starting chemotherapy: Machine learning applied to comprehensive electronic health record data. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort.
  Waisman Malaret, A. J., Chang, P., Zhu, K., Zheng, Y., Newcomb, L. F., Liu, M., … Wagner, A. A. (2021). Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort. The Journal of Urology, 101097JU0000000000002354.
- Editorial Comment on Considerations in the Analysis of Clinical Trial Failure. I.
  Brooks, J. D. (1800). Editorial Comment on Considerations in the Analysis of Clinical Trial Failure. I. The Journal of Urology, 101097JU0000000000002428.
- Protein signatures to distinguish aggressive from indolent prostate cancer.
  Garcia-Marques, F., Liu, S., Totten, S. M., Bermudez, A., Tanimoto, C., Hsu, E.-C. C., … Pitteri, S. J. (2022). Protein signatures to distinguish aggressive from indolent prostate cancer. The Prostate.
- Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25?mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma.
  Chan, E., McKenney, J. K., Hawley, S., Corrigan, D., Auman, H., Newcomb, L. F., … Nguyen, J. K. (2022). Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25?mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc.
- Development and Validation of a Quantitative Reactive Stroma Biomarker (qRS) for Prostate Cancer Prognosis.
  Ruder, S., Gao, Y., Ding, Y., Bu, P., Miles, B., De Marzo, A., … Ayala, G. (2022). Development and Validation of a Quantitative Reactive Stroma Biomarker (qRS) for Prostate Cancer Prognosis. Human Pathology.
- Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.
  Magnani, C. J., Hernandez-Boussard, T., Baker, L. C., Goldhaber-Fiebert, J. D., & Brooks, J. D. (2022). Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer. The Journal of Urology, 101097JU0000000000002490.
- SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
  Rice, M. A., Kumar, V., Tailor, D., Garcia-Marques, F. J., Hsu, E.-C., Liu, S., … Stoyanova, T. (2022). SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Reports. Medicine, 3(2), 100502.
- Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.
  Brady, L., Newcomb, L. F., Zhu, K., Zheng, Y., Boyer, H., Sarkar, N. D., … Nelson, P. S. (2022). Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. Cancer Medicine.
- Bridging the gap between prostate radiology and pathology through machine learning.
  Bhattacharya, I., Lim, D. S., Aung, H. L., Liu, X., Seetharaman, A., Kunder, C. A., … Rusu, M. (2022). Bridging the gap between prostate radiology and pathology through machine learning. Medical Physics.
- Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer.
  Wen, R., Zhao, H., Zhang, D., Chiu, C.-L., & Brooks, J. D. (2022). Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer. Carbohydrate Research, 519, 108598.
- Expanding the Secondary Use of Prostate Cancer Real World Data: Automated Classifiers for Clinical and Pathological Stage.
  Bozkurt, S., Magnani, C. J., Seneviratne, M. G., Brooks, J. D., & Hernandez-Boussard, T. (2022). Expanding the Secondary Use of Prostate Cancer Real World Data: Automated Classifiers for Clinical and Pathological Stage. Frontiers in Digital Health, 4, 793316.
- Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance.
  Filson, C. P., Zhu, K., Huang, Y., Zheng, Y., Newcomb, L. F., Williams, S., … Lin, D. W. (2022). Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. The Journal of Urology, 101097JU0000000000002852.
- The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma.
  Zhang, D., Wornow, S., Peehl, D. M., Rankin, E. B., & Brooks, J. D. (2022). The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma. Translational Oncology, 25, 101518.
- The Role of MARCKS in Metastasis and Treatment Resistance of Solid Tumors.
  Chiu, C.-L. L., Zhao, H., Chen, C.-H. H., Wu, R., & Brooks, J. D. (2022). The Role of MARCKS in Metastasis and Treatment Resistance of Solid Tumors. Cancers, 14(19).
- A review of artificial intelligence in prostate cancer detection on imaging.
  Bhattacharya, I., Khandwala, Y. S., Vesal, S., Shao, W., Yang, Q., Soerensen, S. J., … Sonn, G. A. (2022). A review of artificial intelligence in prostate cancer detection on imaging. Therapeutic Advances in Urology, 14, 17562872221128791.
- Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study.
  Schenk, J. M., Liu, M., Neuhouser, M. L., Newcomb, L. F., Zheng, Y., Zhu, K., … Lin, D. W. (2022). Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study. Nutrition and Cancer, 1–9.
- Multiparametric Magnetic Resonance Imaging and Metabolic Characterization of Patient-Derived Xenograft Models of Clear Cell Renal Cell Carcinoma.
  Agudelo, J. P., Upadhyay, D., Zhang, D., Zhao, H., Nolley, R., Sun, J., … Sriram, R. (2022). Multiparametric Magnetic Resonance Imaging and Metabolic Characterization of Patient-Derived Xenograft Models of Clear Cell Renal Cell Carcinoma. Metabolites, 12(11).
- Factors that influence treatment decisions: A qualitative study of racially and ethnically diverse patients with low- and very-low risk prostate cancer.
  Guan, A., Shim, J. K., Allen, L., Kuo, M.-C., Lau, K., Loya, Z., … Shariff-Marco, S. (2022). Factors that influence treatment decisions: A qualitative study of racially and ethnically diverse patients with low- and very-low risk prostate cancer. Cancer Medicine.
- Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016.
  Srivastava, A. K., Wang, Y., Huang, R., Skinner, C., Thompson, T., Pollard, L., … Bouazzaoui, A. (2016). Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016. Human Genomics, 10 Suppl 1(Suppl 1), 12.
- Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population.
  Lichtensztajn, D. Y., Hofer, B. M., Leppert, J. T., Brooks, J. D., Chung, B. I., Shah, S. A., … Cheng, I. (2022). Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology.
- PlexusNet: A Neural Network Architectural Concept for Medical Image Classification
  Eminaga, O., Abbas, M., Shen, J., Laurie, M., Brooks, J. D., Liao, J., & Rubin, D. L. (2023). PlexusNet: A Neural Network Architectural Concept for Medical Image Classification. Computers in Biology and Medicine , 106594.
- Fusion Gene Detection in Prostate Cancer Samples Enhances the Prediction of Prostate Cancer Clinical Outcomes from Radical Prostatectomy through Machine Learning in a Multi-institutional Analysis.
  Yu, Y.-P., Liu, S., Ren, B.-G., Nelson, J., Jarrard, D., Brooks, J. D., … Luo, J.-H. (2023). Fusion Gene Detection in Prostate Cancer Samples Enhances the Prediction of Prostate Cancer Clinical Outcomes from Radical Prostatectomy through Machine Learning in a Multi-institutional Analysis. The American Journal of Pathology.
- Prosteria - National Trends and Outcomes of More Frequent than Guideline Recommended Prostate Specific Antigen Screening.
  Peterson, D. J., Bhambhvani, H. P., Baird, D. R., Li, S., Eisenberg, M. L., & Brooks, J. D. (2023). Prosteria - National Trends and Outcomes of More Frequent than Guideline Recommended Prostate Specific Antigen Screening. Urology.
- Measuring the multifaceted roles of mucin-domain glycoproteins in cancer.
  Riley, N. M., Wen, R. M., Bertozzi, C. R., Brooks, J. D., & Pitteri, S. J. (2023). Measuring the multifaceted roles of mucin-domain glycoproteins in cancer. Advances in Cancer Research, 157, 83–121.
- PlexusNet: A neural network architectural concept for medical image classification.
  Eminaga, O., Abbas, M., Shen, J., Laurie, M., Brooks, J. D., Liao, J. C., & Rubin, D. L. (2023). PlexusNet: A neural network architectural concept for medical image classification. Computers in Biology and Medicine, 154, 106594.
- Siglec-7/9-sialic acid interactions inhibit T cell immune response in prostate cancer
  Wen, R. M., Stark, J. C. C. S., Garcia-Marques, F., Nolley, H. Z. R., Bertozzi, C. R., Pitteri, S. J., & Brooks, J. D. (2022). Siglec-7/9-sialic acid interactions inhibit T cell immune response in prostate cancer. CANCER IMMUNOLOGY RESEARCH. AMER ASSOC CANCER RESEARCH.
- NUSAP1 Binds ILF2 to Modulate R-Loop Accumulation and DNA Damage in Prostate Cancer.
  Chiu, C.-L. L., Li, C. G., Verschueren, E., Wen, R. M., Zhang, D., Gordon, C. A., … Brooks, J. D. (2023). NUSAP1 Binds ILF2 to Modulate R-Loop Accumulation and DNA Damage in Prostate Cancer. International Journal of Molecular Sciences, 24(7).
- Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort.
  Waisman Malaret, A. J., Chang, P., Newcomb, L., Faino, A., Zheng, Y., Zhu, K., … Wagner, A. A. (2021). Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. Urology Practice, 8(5), 576–582.
- Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study.
  Crump, C., Stattin, P., Brooks, J. D., Sundquist, J., Bill-Axelson, A., Edwards, A. C., … Sieh, W. (2023). Long-term Risks of Depression and Suicide Among Men with Prostate Cancer: A National Cohort Study. European Urology.
- Distinguishing Renal Cell Carcinoma From Normal Kidney Tissue Using Mass Spectrometry Imaging Combined With Machine Learning.
  Shankar, V., Vijayalakshmi, K., Nolley, R., Sonn, G. A., Kao, C.-S. S., Zhao, H., … Brooks, J. D. (2023). Distinguishing Renal Cell Carcinoma From Normal Kidney Tissue Using Mass Spectrometry Imaging Combined With Machine Learning. JCO Precision Oncology, 7, e2200668.
- Induction of phase 2 enzymes in the F-344 rat prostate.
  Jones, S. B., Bhamre, S., & Brooks, J. D. (2004). Induction of phase 2 enzymes in the F-344 rat prostate. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. AMER ASSOC CANCER RESEARCH.
- Adjuvant docetaxel chemotherapy with abbreviated hormonal therapy in patients with high-risk prostate cancer
  Colocci, N., King, C. R., Brooks, J. D., Gill, H. S., Presti, J. C., & Srinivas, S. (2007). Adjuvant docetaxel chemotherapy with abbreviated hormonal therapy in patients with high-risk prostate cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Elevated urinary lipocalin-2, interleukin-6 and monocyte chemoattractant protein-1 levels in children with congenital ureteropelvic junction obstruction
  Yu, L., Zhou, L., Li, Q., Li, S., Luo, X., Zhang, C., … Sun, H. (2019). Elevated urinary lipocalin-2, interleukin-6 and monocyte chemoattractant protein-1 levels in children with congenital ureteropelvic junction obstruction. JOURNAL OF PEDIATRIC UROLOGY, 15(1).
- Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018; 74: 146-54
  Leppert, J. T., & Brooks, J. D. (2018). Re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018; 74: 146-54. EUROPEAN UROLOGY, 74(5), E110–E111.
- Identification of transcripts associated with renal damage due to ureteral obstruction as candidate urinary biomarkers
  Wu, B., Gong, X., Kennedy, W. A., & Brooks, J. D. (2018). Identification of transcripts associated with renal damage due to ureteral obstruction as candidate urinary biomarkers. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 315(1), F16–F26.
- Male infertility is associated with altered treatment course of men with cancer
  Eminaga, O., Li, S., Baker, L. C., Brooks, J. D., & Eisenberg, M. L. (2018). Male infertility is associated with altered treatment course of men with cancer. ANDROLOGY, 6(3), 408–413.
- Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States
  Loft, M. D., Berg, K. D., Kjaer, A., Iversen, P., Ferrari, M., Zhang, C. A., … Roder, M. A. (2018). Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. CLINICAL GENITOURINARY CANCER, 16(1), E181–E192.
- Trends in the incidence and survival of men diagnosed with denovo metastatic prostate cancer in the us and Denmark - a population-based analysis of two national cohorts
  Helgstrand, J. T., Klemann, N., Toft, B. G., Brasso, K., Vainer, B., Lichtensztajn, D., … Roder, M. A. (2017). Trends in the incidence and survival of men diagnosed with denovo metastatic prostate cancer in the us and Denmark - a population-based analysis of two national cohorts. SCANDINAVIAN JOURNAL OF UROLOGY. TAYLOR & FRANCIS LTD.
- SMOKING AND ADVERSE OUTCOMES AT RADICAL PROSTATECTOMY
  Ngo, T., Lee, J., Brooks, J., Nolley, R., Ferrari, M., & Presti, J. (2011). SMOKING AND ADVERSE OUTCOMES AT RADICAL PROSTATECTOMY. JOURNAL OF UROLOGY. ELSEVIER SCIENCE INC.
- Targeted Methylation Sequencing of Prostate Cancer
  Jager, N., Chen, J., Haile, R., Hitchins, M., Brooks, J. D., & Snyder, M. (2016). Targeted Methylation Sequencing of Prostate Cancer. HUMAN GENOMICS. BMC.
- A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment
  Liss, M. A., Schenk, J. M., Faino, A. V., Newcomb, L. F., Boyer, H., Brooks, J. D., … Thompson, I. M. (2016). A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment. PROSTATE CANCER AND PROSTATIC DISEASES, 19(4), 390–394.
- Increased expression of NuSAP gene in recurrent prostate cancer is mediated by E2F
  Gulzar, Z. G., & Brooks, J. D. (2011). Increased expression of NuSAP gene in recurrent prostate cancer is mediated by E2F. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Performance characteristics of PSA in patients undergoing radical prostatectomy.
  Liu, J.-J., Brooks, J. D., Ferrari, M., Nolley, R., & Presti, J. C. (2012). Performance characteristics of PSA in patients undergoing radical prostatectomy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- AN ENVIRONMENT-WIDE ASSOCIATION STUDY (EWAS) ON PROSTATE CANCER
  Lee, J. J., Patel, C. J., Brooks, J. D., & Leppert, J. T. (2013). AN ENVIRONMENT-WIDE ASSOCIATION STUDY (EWAS) ON PROSTATE CANCER. JOURNAL OF UROLOGY. ELSEVIER SCIENCE INC.
- Comprehensive Gene Expression Changes Associated with Mouse Postnatal Kidney Development
  Wu, B., Sahoo, D., & Brooks, J. D. (2013). Comprehensive Gene Expression Changes Associated with Mouse Postnatal Kidney Development. JOURNAL OF UROLOGY, 189(6), 2385–2390.
- Resveratrol-induced gene expression profiles in human prostate cancer cells.
  Jones, S. B., DePrimo, S. E., & Brooks, J. D. (2003). Resveratrol-induced gene expression profiles in human prostate cancer cells. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. AMER ASSOC CANCER RESEARCH.
- Evaluation of Putative Renal Cell Carcinoma Markers PAX-2, PAX-8, and hKIM-1 in Germ Cell Tumors (GCT): A Tissue Microarray Study of 100 Cases
  Sangoi, A., Higgins, J., Brooks, J., Bonventre, J., & McKenney, J. (2011). Evaluation of Putative Renal Cell Carcinoma Markers PAX-2, PAX-8, and hKIM-1 in Germ Cell Tumors (GCT): A Tissue Microarray Study of 100 Cases. MODERN PATHOLOGY. NATURE PUBLISHING GROUP.
- Patient-Reported Long-term Outcomes after Hypofractionated Stereotactic Radiotherapy for Low-risk Prostate Cancer: Evidence from a Prospective Trial
  King, C. R., Brooks, J. D., Gill, H., & Presti, J. C. (2010). Patient-Reported Long-term Outcomes after Hypofractionated Stereotactic Radiotherapy for Low-risk Prostate Cancer: Evidence from a Prospective Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Evaluation of Brachyury Expression in Germ Cell Tumors (GCT) and Clear Cell Renal Cell Carcinomas (CC-RCC): A Tissue Microarray Study of 295 Cases
  Sangoi, A. R., Higgins, J. P., Brooks, J. D., & McKenney, J. M. (2010). Evaluation of Brachyury Expression in Germ Cell Tumors (GCT) and Clear Cell Renal Cell Carcinomas (CC-RCC): A Tissue Microarray Study of 295 Cases. MODERN PATHOLOGY. NATURE PUBLISHING GROUP.
- Evaluation of Brachyury Expression in Germ Cell Tumors (GCT) and Clear Cell Renal Cell Carcinomas (CC-RCC): A Tissue Microarray Study of 295 Cases
  Sangoi, A. R., Higgins, J. P., Brooks, J. D., & McKenney, J. K. (2010). Evaluation of Brachyury Expression in Germ Cell Tumors (GCT) and Clear Cell Renal Cell Carcinomas (CC-RCC): A Tissue Microarray Study of 295 Cases. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP.
- The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy
  Roder, M. A., Berg, K. D., Loft, M. D., Thomsen, F. B., Ferrari, M., Kurbegovic, S., … Iversen, P. (2018). The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy. EUROPEAN UROLOGY FOCUS, 4(3), 360–368.
- Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: a Multi-Center Retrospective Study.
  Patel, P., Harmon, S., Iseman, R., Ludkowski, O., Auman, H., Hawley, S., … Jamaspishvili, T. (2023). Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: a Multi-Center Retrospective Study. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 100241.
- Risks of Alcohol and Drug Use Disorders in Prostate Cancer Survivors: National Cohort Study.
  Crump, C., Stattin, P., Brooks, J. D., Sundquist, J., Edwards, A. C., Sieh, W., & Sundquist, K. (2023). Risks of Alcohol and Drug Use Disorders in Prostate Cancer Survivors: National Cohort Study. JNCI Cancer Spectrum.
- Proteomics analysis of urine and catheter-associated biofilms in spinal cord injury patients.
  Garcia-Marques, F. J., Zakrasek, E., Bermudez, A., Polasko, A. L., Liu, S., Stoyanova, T., … Pitteri, S. J. (2023). Proteomics analysis of urine and catheter-associated biofilms in spinal cord injury patients. American Journal of Clinical and Experimental Urology, 11(3), 206–219.
- Identification of age- and immune-related gene signatures for clinical outcome prediction in lung adenocarcinoma.
  Zhou, A., Zhang, D., Kang, X., & Brooks, J. D. (2023). Identification of age- and immune-related gene signatures for clinical outcome prediction in lung adenocarcinoma. Cancer Medicine.
- Original Proteomics analysis of urine and catheter-associated biofilms in spinal cord injury patients
  Garcia-Marques, F. J., Zakrasek, E., Bermudez, A., Polasko, A. L., Liu, S., Stoyanova, T., … Pitteri, S. J. (2023). Original Proteomics analysis of urine and catheter-associated biofilms in spinal cord injury patients. AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 11(3), 206–219.
- Patient-level factors associated with the use of active surveillance: The talking about prostate cancer cohort.
  Mukand, N., Shariff-Marco, S., Brooks, J. D., Chung, B. I., Leppert, J. T., Frosh, D., … Lu, Q. (2023). Patient-level factors associated with the use of active surveillance: The talking about prostate cancer cohort. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
  Shen, M., Liu, S., Toland, A., Hsu, E.-C. C., Hartono, A. B., Alabi, B. R., … Stoyanova, T. (2023). ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype. British Journal of Cancer.
- ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype
  Shen, M., Liu, S., Toland, A., Hsu, E.-C., Hartono, A. B., Alabi, B. R., … Stoyanova, T. (2023). ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype. BRITISH JOURNAL OF CANCER.
- Spatial transcriptomics identifies candidate stromal drivers of benign prostatic hyperplasia.
  Pollack, A. S., Kunder, C. A., Brazer, N., Shen, Z., Varma, S., West, R. B., … Pollack, J. R. (2023). Spatial transcriptomics identifies candidate stromal drivers of benign prostatic hyperplasia. JCI Insight.
- Risks of Depression, Anxiety, and Suicide in Partners of Men with Prostate Cancer: A National Cohort Study.
  Crump, C., Stattin, P., Brooks, J. D., Sundquist, J., Edwards, A. C., Sundquist, K., & Sieh, W. (2023). Risks of Depression, Anxiety, and Suicide in Partners of Men with Prostate Cancer: A National Cohort Study. Journal of the National Cancer Institute.
- Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study.
  Guan, A., Santiago-Rodriguez, E. J., Chung, B. I., Shim, J. K., Allen, L., Kuo, M.-C., … Shariff-Marco, S. (2023). Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study. BMC Cancer, 23(1), 1191.
- High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker.
  Liu, S., Hawley, S. J., Kunder, C. A., Hsu, E.-C. C., Shen, M., Westphalen, L., … Stoyanova, T. (2024). High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker. Scientific Reports, 14(1), 486.
- MIC-CUSP: Multimodal Image Correlations for Ultrasound-Based Prostate Cancer Detection
  Bhattacharya, I., Vesal, S., Jahanandish, H., Choi, M., Zhou, S., Kornberg, Z., … Rusu, M. (2023). MIC-CUSP: Multimodal Image Correlations for Ultrasound-Based Prostate Cancer Detection. SIMPLIFYING MEDICAL ULTRASOUND, ASMUS 2023. SPRINGER INTERNATIONAL PUBLISHING AG.
- Siglec-7/9 are novel immune checkpoints for prostate cancer
  Wen, R., Stark, J. C., Marti, G. E., Garcia-Marques, F., Zhao, H., Nolley, R., … Brooks, J. D. (2023). Siglec-7/9 are novel immune checkpoints for prostate cancer. JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS.
- UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
  Liu, S., Chai, T., Garcia-Marques, F., Yin, Q., Hsu, E.-C. C., Shen, M., … Stoyanova, T. (2024). UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. Cell Reports. Medicine, 101381.
- Deep learning-based automated pipeline for blood vessel detection and distribution analysis in multiplexed prostate cancer images.
  Karageorgos, G. M., Cho, S., McDonough, E., Chadwick, C., Ghose, S., Owens, J., … Ginty, F. (2023). Deep learning-based automated pipeline for blood vessel detection and distribution analysis in multiplexed prostate cancer images. Frontiers in Bioinformatics, 3, 1296667.
- Response to lao, guan, wang, et al.
  Crump, C., Stattin, P., Brooks, J. D., Sundquist, J., Edwards, A. C., Sundquist, K., & Sieh, W. (2024). Response to lao, guan, wang, et al. Journal of the National Cancer Institute.
- Identification and characterization of intact glycopeptides in human urine.
  Garcia-Marques, F., Fuller, K., Bermudez, A., Shamsher, N., Zhao, H., Brooks, J. D., … Pitteri, S. J. (2024). Identification and characterization of intact glycopeptides in human urine. Scientific Reports, 14(1), 3716.
- 68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial.
  Duan, H., Moradi, F., Davidzon, G. A., Liang, T., Song, H., Loening, A. M., … Iagaru, A. (2024). 68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. The Lancet. Oncology.
- Critical evaluation of artificial intelligence as a digital twin of pathologists for prostate cancer pathology.
  Eminaga, O., Abbas, M., Kunder, C., Tolkach, Y., Han, R., Brooks, J. D., … Bettendorf, O. (2024). Critical evaluation of artificial intelligence as a digital twin of pathologists for prostate cancer pathology. Scientific Reports, 14(1), 5284.
- RAPHIA: A deep learning pipeline for the registration of MRI and whole-mount histopathology images of the prostate.
  Shao, W., Vesal, S., Soerensen, S. J., Bhattacharya, I., Golestani, N., Yamashita, R., … Rusu, M. (2024). RAPHIA: A deep learning pipeline for the registration of MRI and whole-mount histopathology images of the prostate. Computers in Biology and Medicine, 173, 108318.
- Mortality Risks Associated with Depression in Men with Prostate Cancer.
  Crump, C., Stattin, P., Brooks, J. D., Sundquist, J., Sieh, W., & Sundquist, K. (2024). Mortality Risks Associated with Depression in Men with Prostate Cancer. European Urology Oncology.
- AZGP1 deficiency promotes angiogenesis in prostate cancer.
  Wen, R. M., Qiu, Z., Marti, G. E., Peterson, E. E., Marques, F. J., Bermudez, A., … Brooks, J. D. (2024). AZGP1 deficiency promotes angiogenesis in prostate cancer. Journal of Translational Medicine, 22(1), 383.
- ArtHiFy: Artificial Histopathology-style Features for Improving MRI-Based Prostate Cancer Detection
  Bhattacharya, I., Shao, W., Li, X., Soerensen, S. J. C., Fan, R. E., Ghanouni, P., … Rusu, M. (2024). ArtHiFy: Artificial Histopathology-style Features for Improving MRI-Based Prostate Cancer Detection. COMPUTER-AIDED DIAGNOSIS, MEDICAL IMAGING 2024. SPIE-INT SOC OPTICAL ENGINEERING.
- Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
  Newcomb, L. F., Schenk, J. M., Zheng, Y., Liu, M., Zhu, K., Brooks, J. D., … Lin, D. W. (2024). Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer. JAMA.
- Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage.
  Nguyen, J. K., Harik, L. R., Klein, E. A., Li, J., Corrigan, D., Liu, S., … McKenney, J. K. (2024). Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage. Histopathology.
- Incidence and Pitfalls of Adipose Tissue Encountered in Prostatic Transurethral Resections and Related Specimens.
  Wu, D. J.-X., Brooks, J. D., Rizkalla, C., & Sangoi, A. R. (2024). Incidence and Pitfalls of Adipose Tissue Encountered in Prostatic Transurethral Resections and Related Specimens. International Journal of Surgical Pathology, 10668969241265032.
- Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort.
  Liss, M. A., Zeltser, N., Zheng, Y., Lopez, C., Liu, M., Patel, Y., … Leach, R. J. (2024). Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology.
- Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake
  Mukand, N. H., Chirikova, E., Lichtensztajn, D., Negoita, S., Aboushwareb, T., Bennett, J., … Cheng, I. (2024). Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake. CANCER.
- Establishing and characterizing the molecular profiles, cellular features, and clinical utility of a patient-derived xenograft model using benign prostatic tissues.
  Polasko, A. L., Zhang, D., Ramraj, A., Chiu, C.-L. L., Garcia-Marques, F. J., Bermudez, A., … Brooks, J. D. (2024). Establishing and characterizing the molecular profiles, cellular features, and clinical utility of a patient-derived xenograft model using benign prostatic tissues. Laboratory Investigation; a Journal of Technical Methods and Pathology, 102129.
- Risk of Anxiety Disorders in Men With Prostate Cancer: A National Cohort Study.
  Crump, C., Stattin, P., Brooks, J. D., Sundquist, J., Sundquist, K., & Sieh, W. (2024). Risk of Anxiety Disorders in Men With Prostate Cancer: A National Cohort Study. JNCI Cancer Spectrum.
- ARTIFICIAL INTELLIGENCE-ASSISTED PROSTATE CANCER DETECTION ON B-MODE TRANSRECTAL ULTRASOUND IMAGES
  Bhattacharya, I., Vesal, S., Jahanandish, H., Choi, M., Zhou, S., Kornberg, Z., … Sonn, G. A. (2024). ARTIFICIAL INTELLIGENCE-ASSISTED PROSTATE CANCER DETECTION ON B-MODE TRANSRECTAL ULTRASOUND IMAGES. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Stockholm3 in a Multiethnic Cohort: Optimizing Prostate Cancer Screening to Reduce Harm and Improve Equity.
  Brooks, J. D. (2024). Stockholm3 in a Multiethnic Cohort: Optimizing Prostate Cancer Screening to Reduce Harm and Improve Equity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2400941.
- Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer.
  Wen, R. M., Stark, J. C., Marti, G. E., Fan, Z., Lyu, A., Garcia Marques, F. J., … Brooks, J. D. (2024). Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer. The Journal of Clinical Investigation.
- Aggressiveness classification of clear cell renal cell carcinoma using registration-independent radiology-pathology correlation learning.
  Bhattacharya, I., Stacke, K., Chan, E., Lee, J. H., Tse, J. R., Liang, T., … Rusu, M. (2024). Aggressiveness classification of clear cell renal cell carcinoma using registration-independent radiology-pathology correlation learning. Medical Physics.
- Incidence and pitfalls of adipose tissue encountered in prostatic transurethral resections and related specimens
  Wu, D., Brooks, J., & Sangoi, A. (2024). Incidence and pitfalls of adipose tissue encountered in prostatic transurethral resections and related specimens. VIRCHOWS ARCHIV. SPRINGER.
- Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
  Chiu, C.-L. L., Zhang, D., Zhao, H., Wei, Y., Polasko, A. L., Thomsen, M. T., … Brooks, J. D. (2025). Targeting AXL inhibits the growth and metastasis of prostate cancer in bone. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Exploiting Siglec-7/9 immune checkpoints in prostate cancer
  Wen, R., Marti, G. E., Stark, J., Marques, F. J. G., Bermudez, A., Riley, N., … Brooks, J. (2024). Exploiting Siglec-7/9 immune checkpoints in prostate cancer. JOURNAL OF IMMUNOLOGY. AMER ASSOC IMMUNOLOGISTS.
- Intact Glycopeptide Analysis of Human Prostate Tissue Reveals Site-Specific Heterogeneity of Protein Glycosylation in Prostate Cancer.
  Kapp, K. L., Garcia-Marques, F., Totten, S. M., Bermudez, A., Tanimoto, C., Brooks, J. D., & Pitteri, S. J. (2025). Intact Glycopeptide Analysis of Human Prostate Tissue Reveals Site-Specific Heterogeneity of Protein Glycosylation in Prostate Cancer. Glycobiology.
- The olfactory receptor OR51E2 regulates prostate cancer aggressiveness and modulates STAT3 in prostate cancer cells and in xenograft tumors.
  Thomsen, M. T., Busk, M., Zhang, D., Chiu, C.-L. L., Zhao, H., Garcia-Marques, F. J., … Nyengaard, J. R. (2025). The olfactory receptor OR51E2 regulates prostate cancer aggressiveness and modulates STAT3 in prostate cancer cells and in xenograft tumors. BMC Cancer, 25(1), 535.
- Immune repertoire profiling uncovers pervasive T-cell clonal expansions in benign prostatic hyperplasia.
  Pollack, A. S., Kunder, C. A., Ho, C. C., Chou, J., Pollack, A. J., Geisick, R. L., … Pollack, J. R. (2025). Immune repertoire profiling uncovers pervasive T-cell clonal expansions in benign prostatic hyperplasia. The Journal of Clinical Investigation.
- Identification of Molecular Subtypes of Clear-Cell Renal Cell Carcinoma in Patient-Derived Xenografts Using Multi-Omics.
  Qiu, Z., Zhang, D., Garcia-Marques, F. J., Bermudez, A., Zhao, H., Peehl, D. M., … Brooks, J. D. (2025). Identification of Molecular Subtypes of Clear-Cell Renal Cell Carcinoma in Patient-Derived Xenografts Using Multi-Omics. Cancers, 17(8).
- Associations Between Prostate Cancer and Dementia: A Nationwide Study in Sweden.
  Crump, C., Stattin, P., Brooks, J. D., Sundquist, J., Wei, J., Sieh, W., & Sundquist, K. (2025). Associations Between Prostate Cancer and Dementia: A Nationwide Study in Sweden. European Urology Oncology.
- Magnetic Resonance Imaging at second surveillance biopsy after diagnosis in patients with Grade Group 1 prostate cancer in the Canary Prostate Active Surveillance Study.
  Chappidi, M. R., Newcomb, L. F., Zheng, Y., Liu, M., Schenk, J. M., Zhu, K., … Lin, D. W. (2025). Magnetic Resonance Imaging at second surveillance biopsy after diagnosis in patients with Grade Group 1 prostate cancer in the Canary Prostate Active Surveillance Study. The Journal of Urology, 101097JU0000000000004592.
- p53 Expression is Associated with Recurrence-Free Survival in Prostate Cancer: Interaction with PTEN
  Abadchi, S. N., Hawley, S., Auman, H., Brooks, J., & Lotan, T. (2025). p53 Expression is Associated with Recurrence-Free Survival in Prostate Cancer: Interaction with PTEN. LABORATORY INVESTIGATION. ELSEVIER SCIENCE INC.
- The RNA demethylase FTO promotes glutamine metabolism in clear cell renal cell carcinoma through the regulation of SLC1A5.
  Zhao, M., Zhang, D., Jiang, H., Kuganesan, N., Natarajan, S., Pu, L., … Rankin, E. B. (2025). The RNA demethylase FTO promotes glutamine metabolism in clear cell renal cell carcinoma through the regulation of SLC1A5. Science Advances, 11(25), eadv2417.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Specializing In

Prostate Cancer

Practice Locations

Urologic Cancer Program in Palo Alto Palo Alto, CA

Palo Alto, CA

Urologic Cancer Program in Palo Alto

875 Blake Wilbur Dr

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(34 Ratings)

Overall Rating

5.0/5

View Ratings by Category

5.0/5

Friendliness

5.0/5

Explanations

5.0/5

Listens

4.9/5

Care provider's efforts to include you in decisions about your care

4.9/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(276 reviews)

Really enjoyed the video visit. Dr. Brooks was kind, informative, and professional.

Mar 2025

•

Verified SHC Patient

He is good. Very knowledgable and responsive..

Mar 2025

•

Verified SHC Patient

Very knowledgeabe and a great guy.

Feb 2025

•

Verified SHC Patient

Well done

Feb 2025

•

Verified SHC Patient

Very complete with his diagnosis and statistics and comforting to hear his comments and findings.

Feb 2025

•

Verified SHC Patient

Very knowledgeable and answered all my questions

Feb 2025

•

Verified SHC Patient

I appreciate access to such a quality medical professional.

Feb 2025

•

Verified SHC Patient

He was friendly, informative and answered our questions. Never made us feel like he was in a rush.

Feb 2025

•

Verified SHC Patient

Great!

Jan 2025

•

Verified SHC Patient

Dr Brooks remains a superior doctor, genuinely interested in my welfare and health. Jim is up-to-date on current technologies and provides realistic expectations along with optimistic prospects, which is a great comfort for me.

Jan 2025

•

Verified SHC Patient

Dr. Brooks has been my doctor since 2003. We have navigated this disease in the most effective way especially in terms of quality of life. I am enjoying good health. I am indebted to Dr. Brooks for his expertise and wish him well.

Jan 2025

•

Verified SHC Patient

This fellow is a real "doc", communication is A+, narrowed the the issue to me, gathering information from me and responding with a wealth of knowledge and simple understanding vocabulary, i hope i am not on his calendar, but if need an oncologist, he is the doc for my friends and family.

Jan 2025

•

Verified SHC Patient

Excellent doctor and a good guy!

Dec 2024

•

Verified SHC Patient

Very knowledgeable and excellent communicator.

Dec 2024

•

Verified SHC Patient

Very straight forward and direct, which I like. Answered all questions and gave me a feeling of relief about my upcoming procedure. Seems like a very likable, competent person.

Dec 2024

•

Verified SHC Patient

Dr Brooks is spectacular as a doctor and as a person. A wonderful combination.

Nov 2024

•

Verified SHC Patient

Personable, communicative, well informed and expert on subjects.

Nov 2024

•

Verified SHC Patient

Enjoyable and informative consultation

Nov 2024

•

Verified SHC Patient

Dr. Brooks is a great doctor. He is very knowledgeable and personable. He communicates and listens very well. His explanations are very clear and he has a nice sense of humor. He has provided great care to me over the time I have seen him.

Oct 2024

•

Verified SHC Patient

Very thoughtful and professional.

Oct 2024

•

Verified SHC Patient

Great physician. Extremely patient friendly. Extremely knwledgable and clear.

Oct 2024

•

Verified SHC Patient

I like Dr Brooks. I think heâ€™s very knowledgeable and that his advice is practical.

Oct 2024

•

Verified SHC Patient

Dr Brooks is the best. I am deeply appreciative of his care and continued support as we have navigated my prostate cancer.

Sep 2024

•

Verified SHC Patient

Very professional and caring physician

Sep 2024

•

Verified SHC Patient

Dr. Brooks was thoughtful, patient, and informative. While the call was brief, I never felt rushed, got all my questions answered, and came away much more educated.

Aug 2024

•

Verified SHC Patient

Excellent doctor with a.caring attitude and explained everything in detail that was understandable and clear.

Jul 2024

•

Verified SHC Patient

Dr Brooks is a first rate doctor, experienced, empathetic, calm and measured, puts patient concerns first.

Jul 2024

•

Verified SHC Patient

Thank you Dr. Brooks, I learned alot from you, I took notes, and I really REALLY value your careful planning! I especially value you not jumping to recommend ADT or surgery without further testing. Thank you Sir! :)

Jun 2024

•

Verified SHC Patient

Very thorough, informative and professional

Jun 2024

•

Verified SHC Patient

Very easy to talk to - heâ€™s very trustworthy too

Jun 2024

•

Verified SHC Patient

Very knowledgeable understanding and patient physician, clear in explanations and instructions

May 2024

•

Verified SHC Patient

Thorough examination and very helpful information about the situation with my prostate

May 2024

•

Verified SHC Patient

Dr Brooks is an extraordinary doctor who has been an invaluable partner the last several years

May 2024

•

Verified SHC Patient

He was great. Really appreciate his knowledge of research and practice and the thoughtful way we had the conversation. He made me feel confident in him as my doctor because he spoke with me assuming I would understand, instead of the opposite.

Apr 2024

•

Verified SHC Patient

Dr. Brooks is wonderful, very knowledgable and able to explain or describe what your problem is in a very direct and understandable manner.

Apr 2024

•

Verified SHC Patient

Thank you Dr. Brooks for the excellent care you provide.

Apr 2024

•

Verified SHC Patient

I feel very fortunate and thankful that he is my physician.

Apr 2024

•

Verified SHC Patient

The best. Period.

Mar 2024

•

Verified SHC Patient

Very succinct yet comprehensive. Gave me the time to ask questions and didn't make me feel rushed or too elementary in my questions.

Mar 2024

•

Verified SHC Patient

Excellent doctor!

Mar 2024

•

Verified SHC Patient

Dr Brooks is excellent and I am very comfortable doing a video visit with him. It is important to us because we are not in the Bay Area full time and this allows us to continue to see Dr Brooks.

Mar 2024

•

Verified SHC Patient

Thanks

Mar 2024

•

Verified SHC Patient

A Great Human Being!!!

Mar 2024

•

Verified SHC Patient

On a scale of 1-10, I would rate him 20 (twenty).

Mar 2024

•

Verified SHC Patient

He's an excellent and caring doctor.

Feb 2024

•

Verified SHC Patient

I always appreciate hearing from him and sharing his expertise

Feb 2024

•

Verified SHC Patient

Dr. James Brooks is a good doctor and I appreciate his service

Feb 2024

•

Verified SHC Patient

Very professional - understanding the patientâ€™s issues, explaining health and treatment plan.

Feb 2024

•

Verified SHC Patient

Dr Brooks is a great doctor. He took good care of me and answered all my questions. I just cannot thanks hime enough for all the outstanding help from him.

Feb 2024

•

Verified SHC Patient

Dr. Brook is a very good doctor. I will recommend him to my friends.

Feb 2024

•

Verified SHC Patient

Dr. Brooks was excellent.

Jan 2024

•

Verified SHC Patient

Heâ€™s great and very personable, gets an A+ in the bedside manner department.

Jan 2024

•

Verified SHC Patient

Great Dr. to talk and understand the medical problem. He is very humble.

Jun 2023

•

Verified SHC Patient

Dr. Brooks is extremely knowledgeable and expert in his field and presented his analysis and recommendations in a way that I found easy to understand and convincing. He is an outstanding physician!

Jun 2023

•

Verified SHC Patient

Excellent doctor

Jun 2023

•

Verified SHC Patient

DR Brooks is a great doctor with a great manner and personality. We have been very pleased with Dr Brooks and very happy that we found him 10 years ago.

May 2023

•

Verified SHC Patient

Excellent and very knowledgeable. He is very caring and on top of the latest procedures for a patient's care and well being.

May 2023

•

Verified SHC Patient

Excellent and empathetic doctor! Great communicator.

May 2023

•

Verified SHC Patient

I enjoyed my visit with him. I felt he was very thorough and answered all my questions.

Apr 2023

•

Verified SHC Patient

Dr Brooks is a knowledgeable, empathetic doctor and I always appreciate the opportunity to get his perspectives on my prostate cancer. I highly recommend him to others and appreciate the opportunity for video visits as it allows me to keep him as my doctor.

Apr 2023

•

Verified SHC Patient

Great physician!

Mar 2023

•

Verified SHC Patient

Dr Brooks is caring and collaborative, and who partners with you for your health decisions. Dr Brooks is knowledgeable about all of the relevant studies and latest procedures, and therefore very well informed to help guide you to the right decisions.

Mar 2023

•

Verified SHC Patient

Dr Brooks is great, always very helpful and understanding. I feel very secure being followed by him.

Mar 2023

•

Verified SHC Patient

Dr. Brooks is a very well informed, compassionate, caring physician who communicates well and allows his patients to express their concerns. He deals with these concerns carefully and effectively, sharing his expert knowledge in a manner that patients can easily comprehend. Stanford is lucky to have him, as are his patients.

Mar 2023

•

Verified SHC Patient

Dr. Brooks has an uncanny way of providing what feels like a safe place where a patient can feel comfortable talking about sensitive personal information both on video visit or in a treatment room. I admire Dr. Brooks for all the research and teaching.he does and am grateful to have been a patient of his for many years.

Mar 2023

•

Verified SHC Patient

Knowledgeable, friendly, articulate. His medical advice has been a tremendous asset.

Mar 2023

•

Verified SHC Patient

Dr.Brooks is a caring physician. He is very knowledgeable and well experienced. He provided valuable inputs to clarify my questions and understandin gof the treatment and disease itself.

Mar 2023

•

Verified SHC Patient

very good Dr

Mar 2023

•

Verified SHC Patient

Extremely satisfied.

Mar 2023

•

Verified SHC Patient

Discussed issues that concerned me which he felt at this time i should not be worried at this time. Dr Brooks would address my PA concerns with a letter back to her.

Jan 2023

•

Verified SHC Patient

Dr. Brooks is a great resource for all common questions about prostate cancer, treatment options and potential consequences. Very informative and concise expertise. Thank you!

Jan 2023

•

Verified SHC Patient

Heâ€™s terrific, the best!

Dec 2022

•

Verified SHC Patient

A+++ professional! Kind, considerate, expert in his field, genuinely concerned for his patients' well-being.

Dec 2022

•

Verified SHC Patient

I am very confident in Dr Brooks assessment and plan going forward

Dec 2022

•

Verified SHC Patient

I feel very comfortable in his care and think his demeanor is outstanding.

Dec 2022

•

Verified SHC Patient

Excellent Doctor and excellent follow-up care. MP Jr.

Nov 2022

•

Verified SHC Patient

Absolutely excellent

Nov 2022

•

Verified SHC Patient

James Brooks is a class act. I am lucky to be his patient.

Oct 2022

•

Verified SHC Patient

Was seen on time as scheduled, the procedure was handled in an excellent manner, and both the doctor and nurse were very friendly and kept me informed of what was going to be or was done.

Oct 2022

•

Verified SHC Patient

Dr. Brooks is a well respected expert in his field.

Oct 2022

•

Verified SHC Patient

Exceptional doctor, good listener, good information and very empathetic

Sep 2022

•

Verified SHC Patient

Dr Brooks is obviously a knowledgeable and study oriented doctor. He spoke how his oponions are formed and the probability of them known thriugh studies...

Sep 2022

•

Verified SHC Patient

Very friendly. Answered all my questions and was helpful and patient

Sep 2022

•

Verified SHC Patient

Dr James Brooks is an excellent listener and communicates in a clear understandable manner. He is knowledgeable about the most current studies and clinical trials. Dr Brooks partners with you to discuss the alternatives and together think through what is best for you under your the circumstances. Can not think of a better doctor of have. I would highly recommend Dr Brooks to family and friends.

Sep 2022

•

Verified SHC Patient

Great doctor, I have a lot of confidence in his analysis and recommendations.

Sep 2022

•

Verified SHC Patient

Very good doctor as he explains things that allow the patient to understand. Very patient with me and all my questions. Very smart.

Sep 2022

•

Verified SHC Patient

Dr Brooks is THE BEST

Jul 2022

•

Verified SHC Patient

Dr. Brooks was excellent. He made me feel comfortable, listened to my questions and gave me insightful answers. We had a great discussion. He obviously knows his stuff but added the extra human touch that I really appreciated.

Jul 2022

•

Verified SHC Patient

Great Doctor and I would recommend him to others.

Jul 2022

•

Verified SHC Patient

Great doctorâ€”listens, discusses options, summarizes, explains diagnosis/assessment in a thoughtful and understandable manner, and is personable. Appreciate having him as my doctor.

Jul 2022

•

Verified SHC Patient

Very professional!

Jul 2022

•

Verified SHC Patient

Dr Brooks was very easy to talk to. He was down to earth and spoke in terms I could understand. He was a good listener, didn't cut me short and seemed very relaxed, he didn't appear to be in a hurry to see the next patient which made me feel comfortable. He was very congenial and engaging. Additionally, I felt like I was getting the best information from a very knowledgeable guy in the field of prostate cancer. I am grateful I was able to see him.

Jul 2022

•

Verified SHC Patient

Thank you for your time and expertise and answering all my questions.

Jul 2022

•

Verified SHC Patient

Dr Brooks is excellent

Jul 2022

•

Verified SHC Patient

Dr. James Brooks was clear and concise in the conversation he had with me regarding my reason for consultation/visit. I was able to understand the information and recommendations that he provided very well.

Jul 2022

•

Verified SHC Patient

Dr.James Brooks discussed with me all treatment options and side effects with more than enough length. It was great discussion and very clear ðŸ‘ ðŸ‘ Thank you so much.

Jul 2022

•

Verified SHC Patient

Excellent physician. Explained in detail perscribed health plan going forward. Gave me ample time to ask questions and answered all in concise terms

Jun 2022

•

Verified SHC Patient

Dr. Brooks was very informative and gave me the context that enabled me to see clearly the path I should take in the immediate future. He made it clear that I can contact him in the future if I have any questions or concerns. I was very pleased with my consultation.

Jun 2022

•

Verified SHC Patient

James Brooks was very helpful and we discussed action plans.

Jun 2022

•

Verified SHC Patient

Heâ€™s the greatest!

Jun 2022

•

Verified SHC Patient

James has graduated beyond surgery and gave on personal medical view.

Jun 2022

•

Verified SHC Patient

James Brooks is very easy to talk to and very knowledgeable in the field. He provided very informative examples and put me at ease throughout the meeting.

Jun 2022

•

Verified SHC Patient

Very trusting, and knowledgeable, physician. I have complet confidence in his ability to handle my medical needs.

May 2022

•

Verified SHC Patient

I am very fortunate to have such an experienced physician like Dr. Brooks providing the care and skills to deal with my prostate cancer. This means a great deal to me and my family. Thank you!

May 2022

•

Verified SHC Patient

Dr. Brooks is caring and compassionate of his patients.

May 2022

•

Verified SHC Patient

A brilliant, patient doctor!

May 2022

•

Verified SHC Patient

James is the best!

May 2022

•

Verified SHC Patient

Dr. Brooks provides the information I need to assist me in making the best decision at that time.

Apr 2022

•

Verified SHC Patient

Excellent at answering my questions

Apr 2022

•

Verified SHC Patient

Awesome doctor!

Apr 2022

•

Verified SHC Patient

Dr. Brooks is a great doctor.

Apr 2022

•

Verified SHC Patient

Dr Brooks PSA explanation and follow-up plan was very helpful since this was the first time I had an elevated PSA. Dr Brooks greatly relieved my concerns.

Mar 2022

•

Verified SHC Patient

Same comment. Dr. Brooks is an excellent doctor and I would absolutely recommend him to anyone in my situation without reservation!

Mar 2022

•

Verified SHC Patient

Very fond of Dr. Brooks. Expert in his field, great communication, Great manner

Mar 2022

•

Verified SHC Patient

The model physician!

Mar 2022

•

Verified SHC Patient

Dr. Brooks is an excellent doctor and I strongly recommend him to my friends and family members.

Mar 2022

•

Verified SHC Patient

Dr Brooks is excellent communicator and physican.

Mar 2022

•

Verified SHC Patient

I feel very fortunate to have him as my urologist.

Mar 2022

•

Verified SHC Patient

The entire staff are tremendously helpful

Mar 2022

•

Verified SHC Patient

Dr. Brooks is a very knowledgeable & very compassionate doctor. I feel very blessed to have him as my doctor!

Feb 2022

•

Verified SHC Patient

Did that on previous question.

Jan 2022

•

Verified SHC Patient

Doctor James Brooks was extremely cordial and easy to communicate with. Provided easy and helpful information about my prostrate health! Looking forward to our next meeting!

Jan 2022

•

Verified SHC Patient

This was my first meeting/'visit' with Dr. Brooks. He was friendly, patient, he listened, took the time to answer my questions in detail, and showed genuine interest in my well-being. I greatly appreciated his depth of knowledge, and professionalism. I made the right choice, and I highly recommend him to others. Thank you very much Dr. Brooks.

Jan 2022

•

Verified SHC Patient

Dr Brooks was excellent. He 1. Had clearly reviewed my record and clinical data. 2. Was concise and clear about his interruption of my case, recommendations and reasoning for them. 3. Succinctly reviewed pertinent clinical studies justifying his recommendations. I greatly appreciate his expertise and concern for my situation.

Jan 2022

•

Verified SHC Patient

Really appreciated Jay, Dr. Brooks assistant, for his thorough explanation.

Jan 2022

•

Verified SHC Patient

Dr Brooks is an exceptional Doctor. He is the reason I got to Stanford

Jan 2022

•

Verified SHC Patient

Heâ€™s wonderful! Personally and professionally. The best

Jan 2022

•

Verified SHC Patient

I am very thankful for the excellent consultation I had with Dr. Brooks.

Jan 2022

•

Verified SHC Patient

Excellent advise. Trust Dr Brooks without question

Dec 2021

•

Verified SHC Patient

Excellent visit. Very informative and helpful.

Dec 2021

•

Verified SHC Patient

Very good/informative/professional call. Thank you

Dec 2021

•

Verified SHC Patient

THoughtful, knowledgeable, yet also lots of common sense. Easy to talk to.

Dec 2021

•

Verified SHC Patient

Excellent care.

Dec 2021

•

Verified SHC Patient

Very kind and knowledgeable!

Nov 2021

•

Verified SHC Patient

Very patient, answered my question, very good.

Nov 2021

•

Verified SHC Patient

As already explained, Dr Brooks is exceptional and we would recommend him to anyone with urological concerns.

Oct 2021

•

Verified SHC Patient

Dr. Brooks is an excellent doctor that listens well and provides thoughtful answers. I am fortunate to have Dr. Brooks as my doctor.

Oct 2021

•

Verified SHC Patient

Dr. Brooks is a compassionate, caring physician and an expert in his field. I am confident in his insight and recommendations. Heâ€™s the best!

Oct 2021

•

Verified SHC Patient

Very helpful, very good explanations and advice, Dr Brooks shows that he cares.

Sep 2021

•

Verified SHC Patient

Dr. James Brooks knows my issue well.

Sep 2021

•

Verified SHC Patient

Excellent physician. Extremely knowledgeable, great communicator, very concerned for his patients' wellbeing

Sep 2021

•

Verified SHC Patient

As per normal, Dr Brooks was great... put my mind to rest..Barry

Sep 2021

•

Verified SHC Patient

Always a pleasure talking with Dr. Brooks and learning from his extensive experience.

Sep 2021

•

Verified SHC Patient

Great

Jul 2021

•

Verified SHC Patient

A great surgeon and wonderful doctor

Jul 2021

•

Verified SHC Patient

Very personable and caring

Jul 2021

•

Verified SHC Patient

Heâ€™s a great doctor and a very lively and warm human being. Iâ€™m so glad heâ€™s been helping me through my treatment and post op with prostate cancer. Heâ€™s very helpful and reassuring.

Jul 2021

•

Verified SHC Patient

Excellent Doctor. Highly recommend.

Jul 2021

•

Verified SHC Patient

I am very grateful to have Dr Brooks as my urologist. He has saved me from having radiation!

Jul 2021

•

Verified SHC Patient

I contacted Dr. Brooks for a second opinion. He was very helpful and I am grateful. During the discussion it was agreed that the appropriate course was to follow Dr. Feng's recommendations of Hormone Therapy & radiation.

Jul 2021

•

Verified SHC Patient

Excellent!

Jul 2021

•

Verified SHC Patient

Excellent physician

Jun 2021

•

Verified SHC Patient

Excellent physician. Provided excellent quality & quantity of relevant info during an important video visit. Great ability to listen, respond to questions in his field immediately. Sincerely kind, supportive physician.

Jun 2021

•

Verified SHC Patient

I have high regard for Dr. Brooks, not because he has a medical credential but because he is the epitome of a caring and sincere human being who has been blessed with the intelligence to care and assist in the individual journeys of his patients. It is my opinion that combined with a high level of professionalism, intellect and empathy Dr. Brooks is an asset not only to Stanford Medical but to the human race in general.

Jun 2021

•

Verified SHC Patient

wery good

Jun 2021

•

Verified SHC Patient

As the British would say, "top marks." It was a delight to speak with him.

Jun 2021

•

Verified SHC Patient

I feel very comfortable to discuss about my health condition with Dr Brooks and have all my questions answered. Thank you Dr.

Jun 2021

•

Verified SHC Patient

Dr Brooks is knowledgeable, and clear in his explanations. I have full confidence in his advice to me, and I am happy that he is my urologist!

May 2021

•

Verified SHC Patient

As a physician, I recognize the unique challenge in caring for a colleague. He allows me to be just a patient when I need to be. Thanks.

May 2021

•

Verified SHC Patient

I like Dr. Brookes he is fine. If the video visit had worked, it wouldâ€™ve been OK.

May 2021

•

Verified SHC Patient

He's an excellent communicator. Explains concepts very well, listens and answers questions thoroughly, and has an excellent "bedside" manner. He always provides good feedback and followup to any concerns.

Apr 2021

•

Verified SHC Patient

He was knowledgeable, friendly, and professional.

Apr 2021

•

Verified SHC Patient

Excellent - the best.

Dec 2020

•

Verified SHC Patient

Very good.

Apr 2020

•

Verified SHC Patient

Jim Brooks is an exceptional physician and a testament to the quality of the Stanford Medical Program. Rational, patient, resolved.

Mar 2020

•

Verified SHC Patient

Dr. Brooks is the best! He's extremely knowledgeable, shows great empathy and understanding, and is very personable.

Mar 2020

•

Verified SHC Patient

On top of my problem provided concise and understandable solution/suggestion. Very courteous and attentive.

Feb 2020

•

Verified SHC Patient

Dr. James Brooks and PA Dr. Zach and all of the urology/oncology staff are super.

Feb 2020

•

Verified SHC Patient

Doctor Brooks is the best!!!

Dec 2019

•

Verified SHC Patient

Outstanding dr.! (Brooks)

Dec 2019

•

Verified SHC Patient

Highest confidence in Dr. Brooks.

Dec 2019

•

Verified SHC Patient

I was very comfortable. Thank you dr.

Dec 2019

•

Verified SHC Patient

Dr. Brooks is outstanding.

Dec 2019

•

Verified SHC Patient

Dr. Brooks is a terrific physician.

Oct 2019

•

Verified SHC Patient

Dr. Brooks was very professional, caring and considerate. He instills a sense of confidence in his patients and is reassuring in his manner.

Aug 2019

•

Verified SHC Patient

Dr. Brooks is VERY informed & shows great interest & empathy with me!

Jun 2019

•

Verified SHC Patient

Dr. Brooks is an A+ doctor. Confident, caring, NEVER talks down to you, knowledgeable.

Apr 2019

•

Verified SHC Patient

Even though it was my first meeting with Dr. James Brooks, he was very personable, knew his stuff and communicated his info to me like I was a long time patient.

Apr 2019

•

Verified SHC Patient

Dr. Brooks & clinic staff are great!

Apr 2019

•

Verified SHC Patient

Would definitely recommend Dr. Brooks.

Apr 2019

•

Verified SHC Patient

Excellent!!

Mar 2019

•

Verified SHC Patient

Excellent appt. I was the focus of his attention. He was very informative, answered all my questions, was not in a hurry, was very patient, & very concerned about me & my care. On a scale of 1-10, he's a 15!!

Mar 2019

•

Verified SHC Patient

Dr. James Brooks is wonderful. He is very caring and explained my condition. I highly recommend Dr. Brooks to other patients.

Feb 2019

•

Verified SHC Patient

Dr. Brooks is excellent.

Jan 2019

•

Verified SHC Patient

Dr. Brooks is top class.

Dec 2018

•

Verified SHC Patient

World class care!

Nov 2018

•

Verified SHC Patient

Outstanding doctor. Knowledgeable, great manner, invites questions. Explains without ever talking down to you.

Nov 2018

•

Verified SHC Patient

Perfect.

Nov 2018

•

Verified SHC Patient

Very knowledgeable & kind, concerned but not alarming.

Oct 2018

•

Verified SHC Patient

Had a very informative productive meeting to discuss options/alternatives etc.

Sep 2018

•

Verified SHC Patient

Dr. Brooks was the best! As a physician I understand the special nature of managing a colleague's health.... me both patient and colleague when I needed to be. He has the "right stuff."

Aug 2018

•

Verified SHC Patient

Dr. Brooks is the best!

May 2018

•

Verified SHC Patient

All good.

May 2018

•

Verified SHC Patient

Dr. Brooks is a great doctor, perfect combination of engaged caregiver and field expert.

May 2018

•

Verified SHC Patient

Great doctor!

Apr 2018

•

Verified SHC Patient

Dr. Brooks is a exemplary physician and has helped me with concerns of developing prostate cancer.

Mar 2018

•

Verified SHC Patient

Dr. Brooks is really very good to us.

Mar 2018

•

Verified SHC Patient

Dr. Brooks answered all of my questions very well.

Feb 2018

•

Verified SHC Patient

Dr. Brooks communicated about options before the procedure. Following the procedure he was very direct in explaining his analysis. Will recommend Dr. Brooks to anyone facing prostate related issues.

Jan 2018

•

Verified SHC Patient

You are the best.

Dec 2017

•

Verified SHC Patient

Dr. Brooks is very patient, explaining clearly of my conditions & courses of actions.

Dec 2017

•

Verified SHC Patient

Good.

Nov 2017

•

Verified SHC Patient

Good.

Sep 2017

•

Verified SHC Patient

My time is maybe nearly running up. But Dr. Brooks still patiently answered my questions clearly!

Sep 2017

•

Verified SHC Patient

Truly outstanding & human! A treasure!

Sep 2017

•

Verified SHC Patient

Dr. Brooks has been my urologist for the past 18 yrs. Not only has his conservative & careful approach to my condition spared me unnecessary biopsies & procedures, but I have been doing very well under his care. He is also always very comforting & reassuring to me. Thanks to Dr. Brooks, we have established an excellent doctor-patient rapport, & it goes without saying that, as always, my wife & I wish him & his family all the best!

Sep 2017

•

Verified SHC Patient

Very pleased w/info provided.

Aug 2017

•

Verified SHC Patient

Dr. Brooks ? excellent physician/explanations.

Jul 2017

•

Verified SHC Patient

Dr. James Brooks is highly knowledgeable & extremely professional. I highly recommend him.

Jun 2017

•

Verified SHC Patient

Dr. Brooks has been my urologist/oncologist for several yrs I have complete confidence in him and he always approaches me as an equal in all treatment decisions. That is very reassuring and confidence - inspiring.

May 2017

•

Verified SHC Patient

Dr. Brooks is a great doctor. He is very skilled and communicates well with his patients.

May 2017

•

Verified SHC Patient

Everyone seems to be very eager to help and or give information.

Mar 2017

•

Verified SHC Patient

Dr. Brooks is tops - ! Excellent doctor.

Jan 2017

•

Verified SHC Patient

Terrific in every way.

Jan 2017

•

Verified SHC Patient

Outstanding! Outstanding.

Dec 2016

•

Verified SHC Patient

Dr. Brooks is an outstanding doctor. I would HIGHLY recommend him to others.

Nov 2016

•

Verified SHC Patient

Dr. Brooks is awesome.

Nov 2016

•

Verified SHC Patient

Excellent doctor, easy to communicate with.

Nov 2016

•

Verified SHC Patient

The professionalism, courtesy, patience, clarity, reasoning was apparent from the FNP all the way to the surgeon. It was exemplary!! Thank you for their reassurance.

Sep 2016

•

Verified SHC Patient

1. Dr. Brooks was very clear & caring about my medical issues. I like him immediately during my initial visit. 2. I liked his PA, Kate very much. She is top.

Aug 2016

•

Verified SHC Patient

I can't remember if we talked about the next thing to do/follow up.

Aug 2016

•

Verified SHC Patient

He's also an excellent and committed doctor... much to his favor.

Aug 2016

•

Verified SHC Patient

All at all times Excellent.

Aug 2016

•

Verified SHC Patient

Usually I'm more critical but all went very well.

Aug 2016

•

Verified SHC Patient

VERY GOOD EXPERIENCE.

Jul 2016

•

Verified SHC Patient

Gave me good confidence in understanding my problem.

Jul 2016

•

Verified SHC Patient

Would always recommend Dr. Brooks. He is excellent!

Jul 2016

•

Verified SHC Patient

Awesome.

May 2016

•

Verified SHC Patient

Dr. Brooks was very helpful to explain my problem and what is my best option.

Apr 2016

•

Verified SHC Patient

Great doctor!

Apr 2016

•

Verified SHC Patient

Outstanding care!

Mar 2016

•

Verified SHC Patient

Dr. Brooks is the BEST in his field.

Mar 2016

•

Verified SHC Patient

Always outstanding care.

Mar 2016

•

Verified SHC Patient

Dr. Brooks is the best. Keep him on your staff & I'll be a happy man.

Feb 2016

•

Verified SHC Patient

Dr. Brooks is outstanding!

Feb 2016

•

Verified SHC Patient

Exceptional physician.

Feb 2016

•

Verified SHC Patient

I would recommend him to anyone!

Jan 2016

•

Verified SHC Patient

Dr. Brooks is outstanding and I have had excellent treatment.

Dec 2015

•

Verified SHC Patient

Dr. Brooks was absolutely first-rate.

Dec 2015

•

Verified SHC Patient

Dr. James D. Brooks has my full confidence, the epitome of first class bedside manner. IF I ever need surgery I would happily select Dr. Brooks. I dreaded anticipating this appt. Dr. Brooks was perfect.

Nov 2015

•

Verified SHC Patient

Dr. Brooks is SUPERB in addition, he talks with me as an adult who can think.

Nov 2015

•

Verified SHC Patient

One of the best provider.

Sep 2015

•

Verified SHC Patient

Good.

Aug 2015

•

Verified SHC Patient

I would like it if all my care providers were like Dr. Brooks.

Aug 2015

•

Verified SHC Patient

I have confidence in Dr. Brooks.

Aug 2015

•

Verified SHC Patient

Dr. Brooks is an excellent physician. He got me through cancer and I will continue to see him.

Jul 2015

•

Verified SHC Patient

Excellent council.

Jul 2015

•

Verified SHC Patient

It is too bad that someone with such outstanding interpersonal skills spends most of his time in administration.

Jun 2015

•

Verified SHC Patient

Dr. Brooks is best!

May 2015

•

Verified SHC Patient

Dr. Brooks is the best; absolutely fantastic.

Apr 2015

•

Verified SHC Patient

Great work.

Mar 2015

•

Verified SHC Patient

My favorite doctor at Stanford Med.!

Feb 2015

•

Verified SHC Patient

Dr Brooks is a first class physician.

Feb 2015

•

Verified SHC Patient

Great!

Feb 2015

•

Verified SHC Patient

Excellent experience and self satisfaction.

Feb 2015

•

Verified SHC Patient

Perfect in every respect really!!

Dec 2014

•

Verified SHC Patient

I think Dr. Brooks is THE BEST.

Dec 2014

•

Verified SHC Patient

Dr. Brooks has always made me comfortable and confident with his recommendation and findings -

Nov 2014

•

Verified SHC Patient

I was stressed out and overwhelmed but Dr. Brooks did the best he could to help me understand what is going on. I still have more questions.

Nov 2014

•

Verified SHC Patient

Nothing to improve best care ever encountered.

Nov 2014

•

Verified SHC Patient

Dr. Brooks is the BEST!!!

Oct 2014

•

Verified SHC Patient

Very good. Have already recommended this care to others.

Oct 2014

•

Verified SHC Patient

Keep up the good care.

Oct 2014

•

Verified SHC Patient

Excellent!

Sep 2014

•

Verified SHC Patient

Highly recommending to others.

Aug 2014

•

Verified SHC Patient

My experience was very good.

Aug 2014

•

Verified SHC Patient

Dr. Brooks was very nice and informative. He took time to get to know me which I liked.

May 2014

•

Verified SHC Patient

Caring, friendly, thorough.

May 2014

•

Verified SHC Patient

Dr. Brooks is passionate about his speciality and takes time to show his knowledge with me. I have great confidence in his medical opinions.

Apr 2014

•

Verified SHC Patient

Dr. seemed stressed. The clinic was understaffed. I needed a simple procedure done during my appt. but dr. said he was alone & had no staff to perform the procedure.

Apr 2014

•

Verified SHC Patient

James Brooks is you r best advertisement.

Apr 2014

•

Verified SHC Patient

Again, best experience in a health - care facility including extensive experience with my parents.

Apr 2014

•

Verified SHC Patient

Dr. Brooks is an excellent listener & articulate & patient in his responses.

Mar 2014

•

Verified SHC Patient

Dr. visits are great, trying to talk to dr. on phone to review lab results takes an act of GOD.

Feb 2014

•

Verified SHC Patient

I've not had better service.

Jan 2014

•

Verified SHC Patient

Up to date on latest treatment research.

Dec 2013

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

James D. Brooks

Surgical oncologist, Urologic surgeon

Get In Touch

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Urologic Cancer Program in Palo Alto Palo Alto, CA

Urologic Cancer Program in Palo Alto

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(276 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

James D. Brooks

Surgical oncologist, Urologic surgeon

Get In Touch

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Urologic Cancer Program in Palo Alto Palo Alto, CA

Urologic Cancer Program in Palo Alto

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(276 reviews)

Referring Physicians

PHYSICIAN HELPLINE